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ABSTRACT
Accumulation of A� is widely believed to play an early and crucial role in the
pathogenesis of Alzheimer's disease (AD). The central problem in AD research, the
mechanism of A� generation mediated by y-secretase, remains unclear. The present study
has identified a novel cleavage site, s-cleavage, within the transmembrane domain of
amyloid precursor protein (APP) and examined the role of s-cleavage in A� generation.
A novel A� species is produced without y-secretase inhibitor treatment, but is increased
with the treatments in several cell lines. Both MALDI-Mass spectrum and western blot
demonstrate that the novel A� is A�46. Both a dominant negative form of PS1 (D385A)
and double deficiencies of PS1/PS2 abolish A�46 generation, demonstrating the
dependence of s-cleavage on PS. The Indiana mutation of APP enhances A�46
generation. Interestingly, transition state analogues L685,458 and 31C block A�46
generation, whereas applications of non-transition state y-secretase inhibitors l�ad to an
elevated level of A�46.
A�40/42 can be generated from pre-accumulated A�46 in the presence of L685,458.
A�46 is co-immunoprecipicated with PSl. Moreover, A� species which shows the same
migration rate in SDS-PAGE as synthetic A�49 was observed, suggesting that it is the
long-sought A�49. Artificially-made A�49 is processed into A�46. Inhibition of A�46
generation from A�49 by L685,458 diminishes A�40/42 production. These findings
suggest the sequence of e-, s-, and y-cleavages within the TM domain of APP.
A�46 is present in 20,000 x g pellet. The majority of A�46 is resistant to cell surface
trypsinization. Treatment with BFA completely blocks A�46 production. A high dose of
IV

monesin causes partial inhibition of AP46 generation, whereas treatments with NH4Cl,
lactcysitn, or tunicamycin do not affect AP46 level. Furthermore, retention of APP in the
ER with an ER sorting signal abolishes AP46 generation, whereas addition of a TGN
sorting motif does not affect AP46 level. These observations demonstrate that the major
subcellular sites for AP46 generation are the Golgi and TGN.
Collectively, the present study provides new insights into the underlying mechanism of
AP generation.
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CHAPTER!
MOLECULAR BASIS OF ALZHEIMER'S DISEASE
In 1906, Alois Alzheimer, a German psychiatrist, reported at a meeting in Munich an
unusual case of presenile dementia in which a 51-old woman, after suffering for several
years from progressive memory impairment and cognitive disorder, eventually died.
After conducting an autopsy, Alzheimer found two distinct lesions in the patient's brain:
senile plaques and neurofibrillary tangles, which distinguished the case from other
diseases [1]. This is the first documented case of Alzheimer's disease (AD). Once
recognized as a rare disorder in Alzheimer's time, with the increase of life expectancy,
AD has emerged as the most common form of dementia among the elderly. Over four
million Americans and about 20 -30 million people worldwide are currently suffering
from AD [2]. Unfortunately it will cause more serious health problems as the elderly
population increases. Due to its distinct symptoms and growing number of patients,
increased scientific efforts have been devoted to understanding the underlying
mechanism of AD. Although it has been almost one hundred years since the initial report
of AD, effective drugs to prevent this disease have not been found yet, and the disease
remains incurable. However, much progress has been made toward the understanding of
the clinical, pathological, genetic, cellular, and biochemical features of this most
devastating neurodegenerative disease.
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1.1 Some distinct features of AD
AD is clinically characterized by progressive memory loss, language deterioration,
impaired judgment, and disorientation, and eventually results in global cognitive deficits.
The two distinct lesions first discovered by Alzheimer, intracellular neurofibrillary
tangles (called NFT) and extracellular amyloid plaques (also known as senile plaques or
neuritic plaques), have been regarded as two hallmarks of AD. In addition, microscope
views also reveal a loss of neurons in certain regions of the brain such as hippocampus, a
center for memory, and the cerebral cortex, where reasoning, memory, language and
other important cognitive actions take place.
Advances in biochemical pathology, immunocytochemistry and molecular genetics led to
the identification of the main constituents of the two lesions. Neurofibrillary tangles are
intraneuronal deposits containing paired helical filaments (PHFs) that are formed from
the aggregation of hyperphosphorylated tau protein [3, 4]. The soluble form of tau
containing 441 amino acids is one of the longest forms of unfolded native protein,
lacking remarkable secondary structure[5]. The conformational change of tau from
unfolded form into �-sheet structure leads to the highly ordered aggregates of PHF. In
healthy neurons tau protein localized in axons of neurons binds to microtubules through
its 3-4 repeated microtubule binding domains. The axonal microtubules function as tracks
for synaptic vesicles, helping transport neurotransmitters. However microtubules in
neurons of AD patients collapse as a result of abnormal hyperphosphorylation of tau
protein. Recent biochemical and animal model studies indicate that phosphorylation of
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tau at its microtubule binding domain by microtubule affinity regulating kinase (MARK)
under certain conditions dislodges tau from microtubules, thus leading to the further
hyperphosphorylation of tau by GSK3 and Cdk5, which in turn triggers tau aggregation
into filaments and tangles, leading to neuron dysfunction [6].
Amyloid plaques are generally found in large numbers in the limbic and association
cortices [7]. The primary components of amyloid plaques were isolated and sequenced by
Glenner and Wong in 1984 as small peptides with 39-43, predominately 40 and 42,
amino acids[8, 9]. These small peptides designated as AP contain a high proportion of
hydrophobic residues, thus adopting anti-P sheet conformation to form fibrils which
deposits in plaques. AP42, a slightly longer, more hydrophobic form, is particularly
prone to aggregation [10]. Amyloid plaques are surrounded by activated microglia, and
reactive astrocytes. These fibril plaques are often accompanied by many "diffuse" (pre
amyloid) plaques in the same brain regions which are thought to be precursors to amyloid
plaques [2]. Interestingly diffuse plaques predominately contain AP42, indicating AP42
plays a pivotal role in the nucleation of plaques [ 11].

1.2 Hypotheses of the underlying mechanism of AD
Identification of major components in senile plaques and NFT provided clue for
investigating the underlying mechanism of AD. In the search for the causes of AD, both
tau tangles and amyloid plaques have been suspected as the culprit of AD.
1.2.1 Tau tangle theory. The tau tangle hypothesis emphasizes the role of tau tangle in

the pathogenesis of AD. The finding that the number of NFTs correlates well with the
severity of AD supports the tau tangle hypothesis. However, due to the later appearance
3

of NFTs in the brain of AD patient, and the evidence that transgenic mice over
expressing mutant tau did not trigger or enhance amyloid plaque formation, tau tangles
are now believed a downstream factor rather than the initial cause of AD.
1.2.2 Amyloid hypothesis. The amyloid hypothesis, also known as amyloid cascade
hypothesis or AP hypothesis, was first proposed by D.J. Selkoe and J.A. Hardy more than
a decade ago [12, 13] based on the following two lines of evidence: 1) the gene
encoding

p

amyloid precursor protein (APP) is located in chromosome 21 [14-16]; 2)

Downs syndrome patients who have an extra copy of chromosome 21 invariably develop
the neuropathology of AD [17]. The amyloid hypothesis states that cerebral AP
accumulation is the primary influence in AD pathogenesis, and that the rest of the disease
process, including tau tangle formation, results from an imbalance between AP
production and AP clearance [18]. Although this hypothesis has not been universally
accepted, substantial evidence supports this theory. First, most of APP mutations in
familial early onset AD ( FAD) found so far are at or near the P-, y-, or a- cleavage sites,
and these mutations enhance either total AP production or the more toxic form of AP42
generation by favoring

P-

or y- secretase action [19-21]. Second, the cloning of the

presenilin (PS) proteins [22] and the discoveries that AD-causing mutations in PS1 and
PS2 also enhance AP42 production reinforce the amyloid hypothesis [23]. Third, tau
mutations cause severe deposition of NFT and fatal neurodegeneration, but no amy loid
plaque formation[24] indicating that tau tangles can not trigger amyloid plaque formation.
Fourth, transgenic mice co-expressing mutant APP and mutant tau protein increase the
NFT formation, whereas the number of plaques remain unchanged compared to the
number of plaques in mutant APP transgenic mice, suggesting AP accumulation prior to
4

tau alteration in the pathogenesis of AD [25]. Fifth, injection of synthetic A�42 fibrils
into the brain of tau P3 l OL mutation transgenic mice caused fivefold increases of NFT
formation, providing directive evidence that A� fibrils can accelerate NFT formation in
vivo [26]. Sixth, recent studies show that the genetic risk factor of late-onset AD, ApoE,
may be involved in A� metabolism, because ApoE deficient mice expressing mutant
APP show significantly reduced cerebral A� deposition [27]. Finally, growing evidence
supports the idea that genetic variability in A� clearance may contribute to the risk of
late-onset AD [28]. Although the number of amyloid plaques does not correlate well
with the severity of AD, further evidence indicates that memory and cognitive decline in
mild AD patients correlate much better with cortical A� levels than plaque numbers, and
correlate best with the soluble A� pool including soluble A� oligomers [29-31]. Recent
evidence points to an important role of intraneuronal A� as a trigger of the pathological
cascade of events leading to AD [32].
Taken together, biochemical, genetic and transgenic studies largely fit well with the
amyloid hypothesis. The pathological cascade for the process of AD is likely to be: from
amyloid accumulation and deposition to tau hyperphosphorylation and tangle formation
and finally to neuron death. Some therapeutic strategies based on the amy loid hypothesis
aimed at reducing A� level such as using �- and y-secretase inhibitors are undergoing
intensive investigations [33].

1.3 Genetic factors in familial Alzheimer's disease
Epidemiology studies show there are two classes of AD, familial AD (FAD) and
sporadic AD. It has been estimated that inherited form of AD accounts for 5-10% of total
5

AD cases [1]. However, FAD and sporadic AD are phenotypically highly similar or often
indistinguishable, except for age of onset[l]. This finding strongly suggests that studies
on FAD will provide important insights into the mechanism of sporadic AD. Currently
three genes, APP, presenilin 1 and presenilin 2, have been identified to cause autosomal
dominant early onset FAD (AD occurring before age 65), whereas e4 allele has been
found linked with late onset AD [34].
1.3.1 APP mutations. App gene mutations are estimated to account for up to 5% of

FAD [34]. The App gene, located on chromosome 21, encodes a protein called � Amy loid
precursor protein (APP), in which about a dozen missense mutations have been found to
be linked with early onset AD [16, 35]. Although these mutations have been found only
in about two dozen families worldwide, delineation of their genotype-to-phenotype
relationships have provided critical insights into the mechanism of AD. These mutations
are located either immediately before � cleavage site or near a-cleavage site, or shortly C
terminal to the y-secretase site (Fig 1. All tables and figures are located in Appendix),
especially at codon 71 7, where several different mutations have been identified. The two
mutations immediately before the �-cleavage site, also known as the Swedish mutation,
have been shown to favor �-secretase cleavage, thus increasing both A�40 and A�42
generation [20, 36], whereas mutations several amino acids C-terminal to the y-site have
been found to selectively elevate A�42 level, presumably by affecting y-secretase
cleavage [21, 35]. Over-expression of wild-type APP can also lead to early onset AD.
Due to an extra copy of chromosome 21 where the app gene resides, Down's syndrome
patients invariably develop clinical and pathological features of AD if they live over 30
years [37, 38]. They display diffuse plaques, which mainly contain A�2, in their teens
6

and 20s, and tangles a decade later. These findings indicate the critical role of A�,
particularly A�42, in the pathogenesis of AD [39].
1.3.2 Preseinlin mutations.

Mutations in Presenilin 1 (PS1) gene (PSEN1) on

chromosome 14q are the most causative factors in early onset FAD, which accounts for
more than 60-70% of FAD cases. These mutations cause the most aggressive form of
early onset FAD, commonly leading to onset of symptoms before the age of 50 and
demise of the patient in his/her 60s. To date, more than one hundred mutations in PSl
and nine mutations in presenilin 2, the homolog of PS1which is located on chromosome
l q31, have been identified [40]. PSENJ and PSEN2 encode 467 and 448 amino acid
proteins, respectively, which are located primarily in the ER and Golgi apparatus. PSs
comprise eight putative transmembrane (TM) domains. They undergo constitutive
endoproteolysis to generate N-terminal and C-terminal fragments which bind together to
form an active form [41]. Most mutations in PSs are missense mutations that are
predominantly located in highly conserved transmembrane domains. Both transfected
cells and transgenic mouse models have demonstrated that almost all of these mutations
selectively elevate A�2 production [41-43], clearly indicating the essential role that
presenilins play in y-secretase activity. Although PSs have been shown to function in
protein trafficking and apoptosis, substantial evidence supports the idea that presenilins
constitute the catalytic subunit of y-secretase (see y-secretase section). Thus mutations in
PSs directly affect y-secretase activity and specificity, generating more toxic forms of A�.
1.3.3 ApoE polymorphism. While mutations in APP and PSs lead to autosomal

dominant inherited form of early onset AD, the t:4 allele of Apolipoprotein E (ApoE) has
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been found to be the major risk factor for late onset AD. Studies searching for proteins in
human cerebrospinal fluid binding to immobilized A� led to the identification of ApoE,
and the recognition that this gene is localized on chromosome 19q, a region which has
previously been found to link with some late onset AD cases [44]. Further genetic
analysis indicate that the frequency of e4 allele in AD patients is higher than that in the
healthy population, and that while inheritance of one the e4 allele increase the likelihood
of developing AD by 2-5 fold, inheritance of two e4 alleles raise this risk by 4 to 10 fold
[45, 46]. In contrast to the elevated e4 frequency in AD cases, the e2 allele frequency in
AD patients is low, suggesting ApoE2 may have some protective function against AD
[47].
Apolipoprotein E (ApoE) is a plasma glycoprotein containing 299 amino acids. Its N
terminal domain contains the receptor binding site, while the C-terminal domain has the
lipoprotein binding functions [48]. ApoE functions primarily in the mobilization and
redistribution of cholesterol during neuronal growth and after injury [49]. The
polymorphism of ApoE consists of single base changes at codons 112 and 158, which
encode Cysl 12 and Cysl 58 in ApoE2, Cys1 12 and Asp158 in ApoE3, and Asp112 and
Asp158 in ApoE4 protein, respectively [50]. In contrast to the genetic variants in early
onset FAD, the presence of e4 is neither necessary nor sufficient to actually cause the
disease, suggesting that other genetic or environmental factors are required to cause AD.
The e4 allele has been shown to be strongly associated with increased neuritic plaques
and cerebral amyloid angiopathy in Alzheimer's disease [51]. Distinct binding properties
of different ApoE isoforms to A� and tau protein may provide a clue to explain the role
they play in AD pathogenesis. In vitro binding studies shows that ApoE binds to A� in an
8

isoform specific fashion, with ApoE4 binding more rapidly to A� compared to ApoE3
[52]. Specific binding of ApoE4 to A� may enhance A� aggregation or amyloid plaque
formation [53]. Interestingly, ApoE3 and ApoE2 bind to tau protein more tightly than
ApoE4. This finding suggests that ApoE-tau complex may prevent tau from being
phosphorylated, thus reducing tau-tangle formation [54].
1.3.4 Candidate susceptibility genes. Some other susceptibility genes have also been

shown linkages with late onset AD, however these linkages have not been fully
confirmed. a-2-Macroglobulin (a-2M) is a serum pan-protease inhibitor, also expressed
in the brain, that has been implicated in AD on the basis of its ability to mediate the
clearance and degradation of A� [55]. a-2M is also a component of senile plaques. Low
density lipoprotein receptor-related protein (LRP) is the main receptor expressed in
neurons. Genetic associations between two different LRP polymorphisms and AD have
been observed [56]. Both the angiotensin converting enzyme (ACE) and insulin
degrading enzyme (IDE) genes have been reported to be genetically linked with late
onset AD, however these linkages have not been firmly confirmed [57, 58]. Recent
results revealed their functions in degrading A� (see section 1. 7).

1.4 Amyloid precursor protein processing and AP generation
1.4.1 APP. A� is derived from a large type I transmembrane protein, amyloid precursor

protein (APP), by two proteases designated as �- and y - secretase. APP gene has been
cloned and been localized in chromosome 21 [14-16]. It comprises three splicing isoforms:
APP 770, APP 751, and APP 695. They differ in that both APP 770 and APP 751 contain
9

exon 7, which encodes a 56-amino acid motif homologous to a Kunitz-type senne
protease inhibitor domain (KPI). Both APP770 and APP75 1 are widely expressed in
noneuronal cells and also occurs in neurons, while neuronal cells express predominantly
APP695 [1]. All three APP isoforms have a signal peptide at the N-terminus, and a TM
domain near the C-terminus. APP undergoes extensive posttranslational modification
such as 0- and N- glycosylation, sulfation, and phosphorylation through the secretory
pathway. A� is generated by two sequential cleavages: �- site and 'Y- site cleavages. A
portion of APP is first cleaved at the �-site, releasing its large soluble ectodomain
fragment (�-APPs) into the lumen or extracellular space, resulting in a 99-residue C
terminal fragment (CTF99 or C99) which is still embedded in membrane. The resultant
C99 is further processed by 'Y-secretase at the "(-site, generating A�40 or A�42, and a C
terminal fragment (CTF'Y) [59]. Alternatively, APP is first cleaved by a-secretase activity
near the middle of the A� region (between Lys1 6 and Leu 17 of A� sequence), shedding
the long N-terminal ectodomain of APP (a-APPs), and yielding an 83-residue CTF83.
CTF83 is further processed by 'Y-secretase at the "(-site, generating P3 fragment (A� 1 740/42) and CTF"f (60, 61]. Since P3 fragment is not present in amyloid plaques, it seems
to be benign. Thus this process is termed as the nonamyloidogenic pathway, since it
precludes A� formation. Most APP molecules that undergo secretory processing are
cleaved by a-secretase rather than �-secretase, thus only a small amount of APP goes to
the amyloidogenic pathway [60, 61].
1.4.2 a-secretase: a-secretase is a putative protease that cleaves APP between Lys16 and

Leul 7 of A� sequence, generating a soluble APP exdodomain fragment (sAPPa) and
CTFa or CTF83. Although a-secretase has not been well defined, several candidate
10

proteins have been proposed. They are membrane bound ADAM (a disintegrin and
metalloprotease) family proteases including ADAMl 7 (also called tumour necrosis factor
a-(TNF-a-) converting enzyme or TACE )[62], ADAMl 0 [63], and ADAM9 [64].
Currently it is unclear whether one or all of them constitute physiological a-secretsae.
Activation of PKC a-, P-, and e have been widely confirmed to increase a-secretase
activity. However, deletion of the ADAMl 7 or the ADAMl0 gene has been shown to
affecte only regulated form of a-secretase activity, suggesting that an unknown
constitutive a-secretase exists [65]. Since the nonamyloidogenic pathway precludes AP
formation, intensive efforts have been focused on modulating nonamyloidogenic pathway
by increasing a-secretase activity[66]. However there are conflicting data regarding
whether increased a-secretase activity by activation of some isoforms of PKC, such as a
and e could decrease AP production [67-70].
1.4.3 P-secretase. Among a-, P-, and y-secretase, P-secretase is the only secretase that

has been well defined. P-secretase, also called P-site APP-cleavage enzyme (BACE), has
been identified by several groups [71-73]. There are two homologues of P secretase,
BACEl and BACE2. The crystal structure of BACE l with its inhibitor has been
determined at 1.9 angstrom resolution [74]. All these results firmly demonstrated that �
secretase was a membrane bound novel aspartyl protease. BACEl mRNA is found in
brain and other tissues, but it shows high activity only in brain [71]. Similarly to other
proteases, BACEl is expressed as a pre-enzyme localized mainly in the· ER. The pre
domain is cleaved by furin or other proprotein convertases [75] after trafficking through
the Golgi. Over-expression BACEl in cultured cells increased P-cleavage activity [72],
whereas

a knockout of the

BACE1 gene in mice abolished A� generation,
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demonstrating that BACEl is the major �-secretase in brain [76]. Purified BACEl
exhibited high �-secretase activity, indicating that its activity does not require other
cellular co-factors [73]. In addition to the major cleavage at the �-site, BACEl also
cleaves at residues 10 and 11 of the A� sequence (referred to as

W-

site). Another

transmembrane aspartyl protease, BACE2, which has 55% homology to BACEl, shows
similar substrate specificity; however it is not highly expressed in the brain [73]. Thus
BACE2 is thought to play a less important role in A� generation. BACE1 becomes a
prime target for drug discovery in Alzheimer's disease, not only because it is the major �
secretase in brain, but also because BACEl deficient mice were perfectly healthy,
behaved normally, and did not show any side-effects [77].

1.5 y- secretase complex
1.5. 1 Presenilins. y-cleavage is the last step in A� generation, which determines the C

terminal heterogeneity of A�. Since A�42 and A�43 are more hydrophobic, more prone
to aggregation, and more toxic to neurons than A�40, the step which determines the ratio
of A�42 to A�40 is crucial in the pathogenesis of AD. The other feature of y-secretase
that made it more important is that y-cleavage occurs in the middle of a membrane, an
extremely hydrophobic environment where normal enzymatic hydrolysis is impossible.
Thus elucidation of the mechanism of y-secretase cleavage is of great significance in AD
prevention as well as in basic enzymology. Although we are still far from completely
understanding it, much progress has been made toward

elucidating the nature of y

secretase.
Genetic studies have shown that mutations in PS1 lead to the most aggressive form of
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early onset FAD [78]. Mutations in presenilins account for most cases of FAD. More
than one hundred mutations in PS 1 and eight mutations in presenilin2 (PS2) have been
found to be associated with early onset FAD (onset before age 65). Almost all of these
mutations invariably increase the ratio of A�42 to A�40, demonstrating an essential role
of presenilins in the y-cleavage [21 ].
The PS I gene was cloned a decade ago [22]. PS I is localized predominately in the ER
and Golgi bodies. A portion of PS 1 has also been found in plasma membranes and
endosomes. It has eight putative TM domains. PS 1 undergoes endoproteolytic processing
within its large cytosolic Loop between TM6 and TM7, generating NTF and CTF, which
remain bound together forming a stable, heterodimeric PS complex [79] . A major
advance in PS 1 functional studies came from PS knockout mice. Primary neurons from
PS 1 deficient mice showed dramatic reduction in A� production when transfected with
APP [80]. PS 1 and PS2 double knockout cells neither altered APP maturation and
distribution, nor affected a- and �-site cleavage processing, but completely abolished y
secretase activity and A� production, leading to accumulation of C99 and C83, which are
direct y-secretase substrates[8 1 , 82]. These findings firmly demonstrate the essential role
that presinilins play in y-secretase activity.
Another advance in understanding PS 1 function came from mutagenesis studies. PS 1
contains two conserved aspartate residues (Asp257 and Asp386), which are in TM6 and
TM7, respectively. Mutation of either of the two aspartate residues inhibited PS 1
endopreoteolytic processing, diminished A� production, and enhanced accumulation of
C99 and C83, a phenomenon similar to PS 1 knockout. Further studies show mutation of
these two aspartate residues in a natural PS 1 splicing variant, PS 1 �9 mutation that does
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not undergo endoproteloysis but still functions, also blocked A� generation, confirming
that the blockage of y-secretase activity via mutation of the two conserved aspartate
residues is independent of PS I endoproteolysis [83]. These findings plus previous y
secretase inhibition results strongly suggest that y-secretase is an aspartyl protease, that
PS 1 is likely a catalytic subunit of y-secretase, and that the two conversed aspartate
residues likely form an active site of the enzyme. Further studies on PS2 also confirm the
requirement of two conversed aspartate residues [84-86].
More direct evidence that presenilines are catalytic components of y-secretase came from
photoactive affinity labeling studies employing transition state analogue inhibitors to
target the active site of aspartyl protease. Photoactivable transition state analogues have
been found to covalently bind to both the N-terminal and C-terminal fragments of
presenilines, whereas none has been discovered bound to full-length presenilines which
are inactive forms [87, 88]. Interestingly, this inhibitor also has been shown to bind to the
PS 1 �E9 splicing mutant which is not endoproteolytically processed due to its lack of
endoproteolysis site, but is still an active form of presenilin.
Taken together, all these findings strongly support the idea that PS constitutes the
catalytic subunit of y-secretase. However, over-expression PS I did not enhance y
secretase activity, indicating that other cellular cofactors are required for y-secretase
activity. Indeed, y-secretase has been found in a high molecular weight complex (250kD
to 1 000 kD). These findings spurred the search for other y-secretase cofactors.
1.5.2 Nicastrin. Using anti-PS I antibody to immunoprecipitate y-secretase complex,

nicastrin (NCT) was the first protein to be purified and identified in the HMW y-secretase
complex. NCT is a highly glycosylated type I transmembrane protein with 709 amino
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acids colocalized in the ER and Golgi apparatuses. Suppression of NCT expression with
RNAi in Caenorhabditis elegans resulted in a phenotype that is similar to those induced
by the mutations of presenilin homologues in Caenorhabditis elegan.

Co

immunoprecipitation of NCT with full-length APP, C-99, and C-83 has been observed in
several cell lines as well as in human brains. Mutations in a conserved hydrophilic
domain ofNCT increased the ratio of A�42 to A�40, whereas deletion of this hydrophilic
domain abolished the A� generation [89]. Genetic ablation of NCT in Caenorhabditis
elegans and Drosophila resulted in a phenotype similar to the deletion of PS [90-92] .

Fibroblast cells derived from NCT knockout mice completely abolished A� production,
confirming the requirement ofNCT in the functional y-secretase complex [93].
1.5.3 Aphl and Pen-2. Genetic screening of genes in C. elegans that affect y-secretase

activity by monitoring Notch signal pathway (another important pathway in which y
secretase is involved) identified two novel proteins that are indispensable for y-secretase
activity, Aphl [94] and Pen-2 [95]. Two homologue genes in human, Aphl la and Aphl b,
have been identified, both of them encoding proteins that have seven putative
transmembrane domains. Mutation of the conserved GxxxG motif in the fourth TM of
Aphl led to failure of y-secretase assembly and loss of y-secretase activity, indicating its
requirement for y-secretase complex activity [96]. Pen-2 (presenilin enhancer) has been
identified as an enhancer of y-secretase activity in C elegans. It has been predicted as a
transmembrane protein that spans the membrane for two times. Down regulation of this
gene by RNAi technique reduced presenilin fragment accumulation and caused a loss of
y-secretase activity.
Despite the fact that NCT, Aphl , and Pen-2 all affect y-secretase activity, individual
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over-expression of each of them did not increase y-secretase activity, suggesting that they
work together to form a functional complex. Growing evidence shows that first Aph-1
and NCT form a subcomplex to bind to PS, then this subcomplex further binds to Pen-2
to initiate endoproteolysis of PS 1, thus conferring y-secretase activity

[97].

Co

expression these four protein in yeast Saccharomyces cerevisiae, which lacks endogenous
y-secretase activity, successfully reconstituted y-secretase activity, further demonstrating
the necessity and sufficiency of these four proteins in y-secretase complex [98].
In summary, substantial evidence demonstrates that presenilin, NCT, Aphl, and Pen-2
form a functional y-secretase complex, with presenilin as the catalytic subunit of the
multiprotein complex.
1.5.4 Other substrates of y -secretase. In addition to APP, y-secretase has also been

reported to cleave several other type I transmembrane proteins, including Notch[99],
Erb4[ 100], APLPl (APP Like protein-I ), APLP2 (APP like protein2) [ 101], E-cadherin
[ 102], and CD44 [103] within their TM region (except for E-cadherin). Among these
substrates, Notch cleavages have been well studied. Notch is a type I transmembrane
receptor that is essential in determining cell fate during embryogenesis and in adults.
Upon ligand binding, Notch is first proteolytically processed by TACE [ 104] or ADAM
at the S2 site (similar to a-cleavage site in APP), which is 12 amino acid residues away
from the membrane[! 05], releasing its extracellular domain. The resultant membrane
bound fragment is cleaved by y-secretase activity at the S3 site (parallel to y-site in APP)
within its transmembrane region [99], releasing Notch intracellular domain (NICD). Thus
the released NICD translocates into the nucleus, where it acts as a transcription
factor[ l06, 107]. It has been found that PSl deficiency diminished NICD generation and
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that y-secretase inhibitors also blocked S3 cleavage[99], suggesting that both Notch and
APP transmembrane cleavage depend on similar y-secretase activity[80, 99]. Indeed,
recently a new cleavage site in the middle of the Notch TM domain has been found and
designated as the S4 site, which is similar to the y-site in APP[l 08].
1.5.5 &-cleavage: In addition to a-, �-, and y-site cleavages, a new secretase processing

site, referred to as the e-site, has recently been identified by several labs at residue 49 of
the A� sequence using a cell-free system [ 1 09- 1 1 1 ]. A small portion of e-cleavage has
also been shown at residue 52 of the A� sequence. e-sites are close to membrane
boundary unlike the y-site that is at the middle of the membrane. This position is parallel
to the S3 site in Notch. Another similarity between the S3 site and the e-site is that both
cleavages have been shown to be PS dependency; and both can be blocked by y-secretase
inhibitors. Similarly to NICD, the e-cleavage generated product, APP intracellular
domain (ACID), has also been shown to translocate into nuclei to bind to Fe65 protein
and Tiop60, acting as a transcription factor [1 1 2]. However, it is not clear what the
relationship is between y-and e-cleavages, whether it consists of random chopping or
sequential actions.
1 .5.6 y-secretase Inhibitors. y-secretase inhibitors have served as useful molecular

probes for studying y-secretase. Screening protease inhibitors for y-secretase activity has
helped to identify y-secretase as a novel aspartyl protease. Since y-secretase plays a
decisive role in A� generation, much effort has been focused on the search for ideal y
secretase inhibitors. Based on APP sequence, some peptidomimetic inhibitors and their
derivatives such as DAPT, DAPM, and compound E, have been designed and tested, and
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exhibit strong inhibition. Since y-secretase is an aspartyl protease, aspartyl protease
transition state analogues, including L685458 and 31 C, which bind to the active site of y
secretase, have been found. However, the progress of y-secretase inhibitor design has
been hampered by the observation that both S3 cleavage in Notch and e-cleavage in APP,
which generate important transcription factors NICD and AICD, respectively, are also
inhibited by these y-secretase inhibitors. Some isocoumarin based inhibitors have been
reported to specifically inhibit A�42 generation without affecting NICD production [113].
However the subsequent work shows that the inhibition specificity seems controversial
[114]. Recently, some nonsteroidal anti-inflammatory drugs (NSAID) have been reported
to specifically inhibit A�42 production at high concentration [115, 116]. No doubt,
further work needs to distinguish y-site cleavage from e-site and S3 site cleavages to get
ideal inhibitors which potently block A�40/42 production without affecting ACID (e
cleavage) or NICD ( the S3 site in Notch) generation.

1.6 AP clearance
It has been widely accepted that the imbalance between A� generation and clearance is a

causative event in AD pathogenesis. Several peptidases have been reported to degrade A�
both in vitro and in vivo. A� clearance recently has emerged as the second potential
therapeutic approach to treat AD.
1.6.1 Neprilysin.

Neprilysin is a zinc containing endopeptidase. It is an integral

membrane protein with a large extracellular domain which comprises the catalytic site, a
TM domain which anchors the protein in the membrane, and a short intracellular domain.
Since its active site is outside of the membrane, neprilysin is the perfect enzyme for
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digesting secreted peptides.

Neprilysin primarily cleaves peptide bonds next to

hydrophobic amino acids. It has been shown to degrade AP in vitro, mainly at Gly9 and
TyrlO [117-119]. More direct evidence came from in vivo studies. After injection of
radio-labeled AP peptides into rat brain, the labeled AP metabolized rapidly, especially
AP42. However, degradation of the injected AP was blocked by employing thiorphan or
phosphoramidon, two neprilysin inhibitors. Interestingly, infusion of neprilysin specific
inhibitor into the rat hippocampus led to the formation of "diffuse plaque". Moreover,
deletion of neprilysin gene in mice resulted in elevated endogenous AP level, strongly
suggesting that nerilysin plays a critical role in degrading AP42 and AP40 in the brain
[120]. Over-expression of this gene in cultured cell significantly decreased AP level [121].
Comparison of the neprilysin mRNA level and its protein level in brains from healthy
individuals and AD patients shows inverse correlation with amyloid plaque number
[122], further confirming the role of neprilysin in regulating AP level in humans.
1.6.2 Insulysin. Another enzyme, insulin degrading enzyme (IDE), was found to regulate

AP levels both in cultured cells [123, 124] and in vivo [125]. Insulin degrading enzyme
(IDE) is one of the major AP level regulators in neurons. IDE is a thiol zinc
metalloendopeptidase located in the cytosol, endosomes, peroxisomes, and on the cell
surface, degrading both insulin and Ap. IDE deficient mice showed increased cerebral
cortex AP level. Elevated levels of the intracellular signaling domain of APP, which was
recently found to be degraded by IDE in vitro, has also been found in IDE deficient cells
[125]. Moreover, genetic studies have found a linkage of the region of chromosomelOq,
where IDE gene resides, with late-onset AD [57, 126]. However, later studies found
another AP degrading enzyme, plasmin, which is also located in this region. It is hard to
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attribute this linkage to IDE.
1. 6.3 Other enzymes. Angiotensin converting enzyme has also been found to degrade
A�. Interestingly, there is also a genetic linkage between the polymorphism · of this gene
and AD incidence[58, 1 27] . Other enzymes such as endothelin converting enzyme- 1 [128]
and plasmin [1 29], have also been shown to have the capability of degrading A�.

1. 7 Conclusions and prospects
Alzheimer' s disease is a devastating neurodegenerative disease, characterized by memory
loss and other cognitive dysfunctions. Among the two hallmarks, amyloid plaques and
their main component A� play a central role in the pathogenesis of AD. Three genes
linked with early onset AD all directly affect A�42/43 generation, whereas one gene
which is associated with late onset AD, ApoE, may be involved in A� clearance or
toxicity. �-cleavage enzymes have been cloned and well defined as membrane bound
aspartyl proteases. a-secretases have been suggested as metalloproteases and several
candidates have been proposed. The aspartyl protease nature and its four essential
components have been identified for y-secretase complex. Several genes involved in A�
degradation and clearance have also been identified. However, it is not clear what the
nature of y secretase is? What is the relationship between y-cleavage and £-cleavages?
Are the y- and the £-sites cleaved by the same secretase, or by similar but different
enzymes? This is an important issue for y-secretase inhibitor design aimed at reducing A�
without causing any side effects, because both AICD and NI CD have important
physiological functions. Further work needs to address the following issues. How do
FAD mutations in APP and in PS affect £-cleavage? What is the role of intracellular A�?
How does A� affect tau tangle formation? How do the genetic mutations in the genes
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involved in A� clearance affect A� accumulation? Addressing these issues will
doubtlessly lead to new approaches to cure AD.
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CHAPTER 2
IDENTIFICATION OF A NEW PRESENILINDEPENDENT �-CLEAVAGE SITE WITHIN THE
TRANSMEMBRANE DOMAIN OF AMYLOID
PRECURSOR PROTEIN
This chapter is a slightly revised version of a paper by the same name published in the
Journal of Biological Chemistry in 2004 by Guojun Zhao, et al:
Zhao, G., et al., Identification of a new presenilin-dependent zeta-cleavage site within the
transmembrane domain of amyloid precursor protein. J Biol Chem, 2004. 279(49): p.

50647-50.
My use of "we" in this chapter refers to my co-authors and myself. I contributed most of
the data and most of the writing.

Abstract
y-secretase cleavage of �-amyloid precursor protein (APP) is crucial in the pathogenesis
of Alzheimer's disease (AD), because it is the decisive step in the formation of the C
terminus of �-amyloid protein (A�) and because the cleavage at A�42 is strongly linked
to the disease. According to the amyloid hypothesis, the longer A� is more
amyloidogenic and more pathogenic. Studies have also shown that the intracellular
generation and accumulation of the long form of A� may account for the
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neurodegenerative toxicity of A�. To better understand the molecular events involved in
y-secretase cleavage of APP, in this study we report the identification of a new
intracellular long A� species containing residues 1 -46 (A�46), which led to the
identification of a novel l;-cleavage site between the known y- and s-cleavage sites within
the transmembrane domain of APP. Our data clearly demonstrate that the new l;-cleavage
is a presenilin-dependent event. It is also noted that the new l;-cleavage site at A�46 is the
APP71 7 mutation site. Furthermore, we show that the new l;-cleavage is inhibited by y
secretase inhibitors known as transition state analogs but less affected by inhibitors
known as non-transition state y-secretase inhibitors. Thus, the identification of A�46
establishes a system to determine the specificity or the preference of the known y
secretase inhibitors, by examining their effects on the formation or turnover of A�46.

2.1 Introduction
In the brain of Alzheimer's disease (AD) patients, one of the characteristic pathological
features is the deposition of amyloid protein in the parenchyma and in the walls of
meningeal and cortical blood vessels. These amyloid deposits are principally composed
of the 39-43 amino acid residue amyloid �-peptide (A�), which is derived from a large �
amyloid precursor protein (APP). Now it is well established that, in the amyloidogenic
pathway, APP is first cleaved at the N-terminus of A� sequence by an enzyme named �
secretase, to produce a soluble ectodomain, sAPP�, and a membraneanchored
C-terminal fragment, CTF�. CTF� is then subsequently cleaved within the
transmembrane domain by another enzyme, referred to as "y-secretase" to produce the
full-length A� and the intracellular domain (AICD) [1 ]). �-secretase has been identified
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as a type I membrane aspartyl protease [72, 73]. The findings that knockout of presenilin
1(PS1) and PS2 results in the abolishment of the y-secretase cleavage of APP and that
two aspartate residues in two transmembrane domains of presenilin have been identified
as critical for the y-secretase activity suggest that presenilin may be the y- secretase [8083]. Recently, several other molecules, namely, nicastrin, Aph-1, and Pen-2, have been
identified as essential components of the "y-secretase" complex of which presenilin may
function as the catalytic subunit [130].
Most of the A� species contain 40 or 42 amino acids. Recently, sequence analysis
revealed that the N-terminus of AICD starts at residue 50 of the A� sequence, which is 79 amino acids away from the C-termini of A�40 and A�42. This led to the finding of the
e-cleavage site between A�49 and A�50 [109-111, 131]. Now the cleavage at
A�40/42has been
specifically referred to as y-cleavage site[11O]. The identification of this e-cleavage site,
which is equivalent to the S3 cleavage site in Notch 1, and the identification of the S4 site
in Notch 1, which is equivalent to the y-cleavage site at A�40/42in APP, further indicate
that APP and Notch 1 undergo a similar intramembranous process, namely the y (S4) and
e(S3) cleavages[108]. However, neither the intermediate A� peptide, which ends at the E
cleavage site, nor the C-terminal fragment, which starts with an N-terminus generated by
y-cleavage, has ever been detected. One possibility is that y- and e-cleavages occur
simultaneously. The other possibility is that there may be additional cleavages(s) between
y- and e-cleavages. Here we report that, in our effort to determine these possibilities, we
successfully identified a novel A�-containing peptide in living cells. Using mass
spectrometry, we determined this A� speciesas A�46 and this led to the identification of a
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new cleavage site at AP46, which we designated as ('.;-cleavage site following the tradition
by which the APP processing sites have been named. It is notable that the newly
identified ('.;-cleavage site is the AD-linked APP717 mutation site.

2.2 Materials and Methods
2.2.1 Materials. y-secretase inhibitors, namely, y-secretase inhibitor IX (DAPT), y
secretase inhibitor XVI y-secretase inhibitor XVIII (Compound E), y-secretase inhibitor
XIX (XIX), y-secretase inhibitor X (L-685,458) and y-secretase inhibitor XVII (WPE-III31C, 31C) were purchased from Calbiochem and dissolved in dimethy 1 sulfoxide
(DMSO). A�O was purchases from Biopeptide (California). AP42 and AP43 were
purchased from American Peptide (California).
2.2.2 Cell lines. Human neuroblastoma Ml 7 cells, human glioma HS683 cells, and
human embryonic kidney 293 cells were purchased from American Type Cell Collection.
All stably transfected N2a cell lines were established and maintained as described
previously[132] . All cells were maintained in DMEM supplied with 10% FBS.
2.2.3 Immunoprecipitation and Western blotting. Eight hrs after treatment with
inhibitors, cells were harvested and lysed in Western blot lysis buffer (50 mM Tris-HCl,
pH 6.8, 8 M urea, 5% P-mercaptoethanol, 2% SDS, and protease inhibitors). Secreted AP
was immunoprecipitated from conditioned media using a AP-specific antibody 6E10
(Senetek). Both cell lysates and the immunoprecipitates were analyzed by 10%
Bicine/urea SOS-PAGE or 10-18% regular SOS-PAGE. After transferred to a
polyvinylidene fluoride membrane (Millipore) and probed with specific antibodies, the
immuno-reactivity bands were visualized using ECL-Plus (Amersham Biosciences).
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2.2.4 Vector construction and transiently transfection. APPswN717F vector

harboring both Swedish and Indiana mutations of APP were generated through site
directed mutagenesis system (Stratagene), using Swedish mutant APP695 as a template.
Transiental transfection was performed uing Lipofectamine 2000 (Invitrogen) according
to menufacture's instruction.
2.2.5 Mass spectrometric analyses. N2a cells cultured in the presence of DAPT were

lysed with 1% NP-40 in IP buffer (50 mM Tris/HCl, pH7.4, 150mM NaCl, 0.5% sodium
deoxycholate, 5mM EDTA, protease inhibitor cocktail). After centrifugation at 20,000 xg
at 4 °C for 15 min, the supernatant was diluted with equal amounts of IP buffer to bring
down the concentration of NP-40 to 0.5%. The intracellular A� species were
immunoprecipitated using 6E10. The immunoprecipitate was eluted from beads with a
buffer of 1% TF A and 45% Acetonitrile and then subjected to Matrix-assisted laser
desorption /ionization mass spectrometric (MALDI-MS) analysis performed on a
Voyager-DE STR mass spectrometer as described previously[l33].

2.3 Results
2.3.1 Identification of a new intracellular AP species. N2a cells stably expressing wild

type PS I (PSlwt) and the myc-tagged Swedish mutant APP (APPsw), which have been
used in previous studies [132, 134], were treated with or without y-secretase inhibitors:
DAPT, DAPM, compound E, and XIX. The cell lysates were analyzed by 10-18%
Tris/Glycine SOS-PAGE followed by Western blotting, using either 6El0,

an

monoclonal antibody specific to residues 1-16 of human A�, or Cl5, an antibody raised
against the C-terminal 15 amino acids of APP. As shown in Fig. lA, in agreement with
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previous reports, treatment with these inhibitors resulted in the accumulation of the
Cterminal fragments of APP, namely, CTF�, and CTFa, generated by �- and a-secretases,
respectively, as detected by C l 5 (compare lanes 2, 3, 4, and 5 with lane 1, top panel). The
identities of these CTFs produced by this cell line have been described in a previous
study[134]. Surprisingly, when the same samples were probed by 6E l0, a band, which is
tentatively labeled as A�46 (Fig1B, top panel lane 1) and has a migration rate much faster
than that of CTF� but slightly slower than those of synthetic A�40, AP42, and A�43
(compare lane 1 with lanes 6 and 7, top panel Fig 1B), was detected in untreated cells
when the blot was exposed to the film for prolonged time. More interestingly, this band
was markedly increased in cells treated with y-secretase inhibitors ( compare lanes 2, 3, 4,
and 5 with lane 1, top panel in Fig l B). The fact that this band was not detected by C15,
but detected by 6E10 suggests that it is more likely a novel intracellular A�-containing
peptide with a higher molecular mass than AP43. The same samples were also analyzed
by 10% Bicine/urea SDS-PAGE as described previously[135] . As shown in FigB,
bottom panel, this new intracellular AP species (lanes 1 to 5) migrated much faster than
A�40/42and A�43 (lanes 6 and 7), indicating that this new A� speciesis more
hydrophobic than AP43. Next, we examined the effects of these inhibitors on the
formation

of secreted

AP.Secreted

AP

in

conditioned

media

(CM)

was

immunoprecipitated with 6E10 and analyzed by Bicine/urea SDS-PAGE followed by
Western blotting using 6E10. As shown in the bottom panel of Fig. l A, secreted AP40
and A�42 were detected in CM of untreated cells (lane 1) but not detected in CM of cells
treated with inhibitors(lanes 2 to 5), a result consistent with many previous studies.
To determine the physiological relevance of this new AP species, we examined its
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presence in other types of cells. As shown in the top panel of Fig.2, in the presence of
3nM compound E, this new A� specieswas also detected in human embryonic kiyney
HEK293 cells( lane 2), human glioma HS683 cells (compare lane 4 with lane 3) and
human neuroblastoma Ml 7 cell (compare lane 4 with lane 5) without overexpressing
APP. The new A� species migrated much faster than A�40/42(compare lanes 2, 4, 6 and
8 with lane 9) in a Bicine/urea SDS-PAGE. Since the blot was overexposed to visualize
the new A� speciesproduced from endogenous APP, the densities of the bands
corresponding to full-length APP (fAPP) and other non-specific or unknown bands were
exaggerated. The same results were observed when DAPT, DAPM, and XIX were used
(data not shown). The detection of this new A� species in different types of cells
indicates the physiological relevance of this peptide. Specifically, the detection of this
new A� speciesin cells without overexpressing APP indicates that this new A� speciesis a
normal metabolic product of APP.
2.3.2 Identification of a new �-cleavage site at AP46. The detection of the new

intracellular long A�-containing peptide prompted us to determine whether it is the
longsought intermediate A�-containing peptide, A�49, generated by e-cleavage. To
determine the identity of these novel intermediate A�-containing peptides, mass
spectrometric analysis was carried out. The new intracellular A� species was
immunoprecipitated with 6El0 from the lysates of cells treated with DAPT, which causes
increased accumulation of this peptide as observed in Fig 1. The immunoprecipitate
complexes were analyzed by MALDI-MS. As shown in Fig. 3, a major spectral peak with
a mass of 4927 .52, which is in agreement with the expected mass of 4926 for A�46, was
observed. Thus, the new A� specieswas identified as A�46. This result is in agreement
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with the Western blot results that show that the new A� speciesis larger and more
hydrophobic than A�43, suggesting that this new A� speciesis longer than A�43 at the
hydrophobic C-terminus (Fig lB). Thus, we identified a new cleavage site at A�46 within
the transmembrane domain of APP between the known y-cleavage site at A�40/42and the
e-cleavage site at A�49. We

named this new cleavage site as "�-cleavage" site,

following the tradition by which other APP processing sites were named. It is noted that
in addition to A�46, a weak spectral peak corresponding to A�43 (measured
mass=4614.86; expected mass=4615) was detected in the immunoprecipitate.
2.3.3 �-cleavage is PSI-dependent. The novel finding that the new �-cleavage product

A�46 was not inhibited, but rather increased by the known y-secretase inhibitors DAPT,
DAPM, compound E, and XIX prompted us to determine whether �-cleavage is
dependent on presenilin. To this end, we examined the effect of the dominant negative
aspartate mutant PS1 on the formation of A�46. In addition to the cells that stably
express both APPsw and PS 1wt used in the above experiments, another line of cells,
APPsw/PSl(D385A), which stably expresses both APPsw and the dominant negative
mutant PSl(D385A) and has been used in a previous study [132], was employed. Cells
were treated with or without 0.5 µM DAPT for 8 hours. The cell lysates and the secreted
A� immunoprecipitated from CM were analyzed by 10-18% SDS-P AGE followed by
Western blotting using specific antibodies. As shown in the top panel of Fig.4 top panel,
full-length PSl was detected in all cells transfected with APPsw and with either wild type
PSl or dominant negative PSl mutant. The PSl processing product, the N-terminal
fragment of PS 1, was detected in cells expressing wild type PS 1 (lanes 1 and 2, top
panel), but not in cells expressing the dominant negative PSl(D385A) mutant (lanes 3
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and 4, top panel), which has been shown not to undergo endoproteolytic processing [83].
As shown in the middle panel of Fig.4, in the presence of DAPT, A�46 was detected in
cells doubly transfected with APPsw and wild type PS I (lane 2) with concomitant
decrease in secreted A� (bottom panel. Lane 2). Interestingly, A�46, as well as secreted
A�, was not detected in cells expressing dominant negative PS1 mutant, regardless of the
presence or absence of DAPT (lanes 3 and 4), indicating that A�46 formation is PS1dependent.
The PS dependence of A�46 formation was confirmed by using PS1/2 double knockout
cells. Both PS1/PS2 wild-type and double knockout cells were transiently transfected
with either Lacz or APPsw695 and cultured in the presence or absence of compound E
for 12 h. As shown in Fig5A, A�46 was only observed in PS1/PS2 wild-type(lane8) but
not in double knockout cells(lane4) analyzed by both 10/18% SDS-PAGE(top panel) and
10% Bicine/urea SDS-PAGE(bottom panel), demonstrating the PS dependence of the
generation of A�46. As expected, secreted A�40/42were only detected from PS1/PS2
wild-type cells (Fig5B)
2.3.4 Transition state analogs inhibit �-cleavage. The data presented in Fig. 1 show that

the known y-secretase inhibitors DAPT, DAPM, compound E, and XIX, at the
concentrations used, completely inhibited the formation of secreted A�40 and A�42
produced by y-cleavage, but have less effect on the formation of A�46 produced by �
cleavage. This observation raises a possibility that these inhibitors may have differential
effects on y- and �-cleavages. In this regard, it was noted that the inhibitors tested,
namely DAPT, DAPM, compound E, and XIX are known as non-transition state
inhibitors. This prompted us to determine the effect of the inhibitors known as transition
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state inhibitors on the new �-cleavage. We performed a series of dose-curve experiments
to characterize these transition state and non-transition state y-secretase inhibitors. N2a
cells expressing both APPsw and PS1wt were treated with various known y-secretase
inhibitors at various concentrations. As shown in Fig.6, in cells treated with DAPT,
DAPM, compound E, and inhibitor XIX (lanes 10 to 17 and lanes 20 to 27), a dose
dependent decrease in secreted A�40 and A�42 in CM (compare with samples from
untreated control cells in lanes 9 and 1 9, lower panel) and, specifically at the lower range
of concentrations of these inhibitors, a concomitant increase in CTF� and A�46 (upper
panel) were observed for all these inhibitors. Surprisingly, it was found that the newly
identified A� speciesA�46 was not detected in the cells treated with transition state
analogs, L-685,458 and 31C (lanes 2 to 8, upper panel), though these inhibitors caused a
marked and dose-dependent decrease in secreted A�40 and A�4 2 in CM ( compare lane 2
to 8 with lane 1, lower panel). This result reveals an important notion that s-cleavage,
which is responsible for the formation of A�46, is specifically inhibited by inhibitors
known as transition state analogs and is less affected by inhibitors known as nontransition
state inhibitors. All inhibitors examined at the ranges of concentrations used were found
to have no effect on the cell growth and the expression and processing of PS 1 ( data not
shown).
2.3.5 The Indiana mutation of APP enhances AP46 generation. Knowing that s

cleavage site is the known V717 mutation site, we next examined the effect of Indiana
mutation of APP on A�46 generation. As shown in fig 7 the level of A�46 generated
from both APPswN717F is much higher(Fig 7 top panel lane4) than that of APPsw(Fig7
top panel lnae2), demonstrating that V7 17F enhances s-cleavage. Consistent with
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previous reports, the ratio of A�42 to A�40 generated from APPswN717F (Fig7 lane3
bottom panel) is higher than that of APPsw (Fig7 lane1 bottom panel).

2.4 Discussion
In this study we detected a new intracellular A�-containing peptide, A�46. The presence
of A�46 in intact cells was confirmed in different types of cells. Specifically, the
detection of A�46 in cells without over-expressing APP indicates that this new A�
species is a normal metabolic product of APP. The finding of this new intracellular A�46
is also supported by recent observations that A� species ending at residue 46 can be
detected in human tissue of subjects with and without AD[l36, 137]. It is noted that
A�46 exists at very low concentration in the absence of inhibitors and can only be
detected by Western blotting after prolonged exposure of the blot, indicating its rapid
turnover in living cells.
The short life of this intermediate and its low concentration may account for the difficulty
in detecting it in living cells. In addition, the intracellular presence of A�46 may explain
why it has never been detected previously in conditioned media. The identification of this
new A�46 species offers several novel insights into the mechanism of the normal and
pathogenic intramembranous processing of APP and the formation of A�.
First, the identification of A�46 reveals a novel cleavage site, [;-cleavage site between the
two known y- and a-cleavage sites. Our data also clearly reveal that this new [;-cleavage
occurs as a presenilin-dependent event, indicating that it is a new intramembranous
cleavage of APP by y-secretase or related protease activity. Moreover, the facts that A�46
can be detected in the absence of inhibitors, and it is the predominant intracellular A�
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speciesas determined by both Western blot and mass spectrometry analyses strongly
indicate that the cleavage site at AP46 is another major cleavage site in APP, besides the
known y-cleavage site at AP40/42and the e-cleavage site at AP49. It is also noted that the
new �-cleavage site at AP46 is the site at which the AD-linked APP mutation, APP7I 7
mutation also known as London mutation, occurs[35, 138]. Thus, our finding reveals an
interesting fact that the well characterized AD-linked APP7I 7 mutation actually occurs at
a major APP processing site, the �-site near the C-terminus of Ap. Also the other well
characterized AD-linked APP mutation, the Swedish mutation occurs at another major
cleavage site, the P-site at the N-terminus of Ap.
Second, our dose curve experiments clearly demonstrate that, at the lower range of
concentrations, DAPT, DAPM, compound E, and inhibitor XIX cause dose-dependent
decrease in secreted AP40 and AP42 and concomitant increase in AP46, suggesting a
possible precursor-product relationship between AP46 and AP40/42. This hypothesis is
also supported by the fact that AP46 contains the y-cleavage site at AP40/42and that
AP46 is detectable in living cells in the absence of any inhibitors. However, the
observation that �-cleavage can be differentially inhibited by y-secretase inhibitors known
as transition state analogs, but less affected by the inhibitors known as non-transition
state inhibitors also raises a possibility that �-cleavage may be catalyzed by a y-secretase
like activity. And this y-secretase-like activity is also dependent on PS I or a PSI -like
protein and can be specifically inhibited by transition state analogs, but it is different
from the one that catalyzes the y-cleavage and can be inhibited by both transition state
and non-transition state inhibitors. According to this model, the dose-dependent decrease
in secreted AP40/42and the concomitant increase in AP46 caused by non-transition state
33

inhibitors at the lower range of concentrations may be related to the substrate availability,
i.e. when the true y-secretase, which cleaves APP at A�40/42, is inhibited, it makes more
CTF� available for the putative y-secretase-like activity, which produces A�46. At higher
ranges of concentrations, these inhibitors also caused dose-dependent increase of CTF�,
suggesting an allosteric mechanism of the inhibitory effects of these inhibitors on the
turnover of A�46 and CTF�.
Third and more importantly, the identification of A�46 made it possible to determine the
specificity of the known y-secretase inhibitors. To our knowledge, most of the known y
secretase inhibitors have shown no difference in inhibiting the y- and E-cleavage as
determined by their inhibitory effects on the generation of secreted A� and the APP
intracellular domain(AICD), with the exception of isocoumarin "JLK", which remains
controversial[ l 13, 114]. However, our experiment examining the effects of the known
inhibitors on the formation and turnover of the newly identified A�46 led to a novel
finding that the newly identified s-cleavage is specifically inhibited by inhibitors known
as transition state analogs and is less affected by inhibitors known as nontransition state
inhibitors. According to the amyloid hypothesis [1], the longer and more hydrophobic
and more amyloidogenic A� is more toxic and pathogenic. In this regard, it is notable that
DAPT, DAPM, compound E, and XIX, which were previously known to inhibit the
formation of secreted A�, cause an intracellular accumulation of an even longer A�
species, A�46 either produced by the same y-secretase, which also catalyzes the cleavage
at A�40/42, or by a new y-secretase-like activity that specifically catalyzes the cleavage
at A�46. This finding provides information important for the strategy of prevention and
treatment of AD aimed at the design of y-secretase inhibitors. Therefore, the observation
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that �-cleavage is differentially inhibited by so called transition state and is less affected
by non-transition state inhibitors is significant because it establishes, for the first time, a
system to determine the specificity or the preference of the known y- secretase inhibitors,
by examining their effects on the formation or turnover of A�46. In general, the
identification of the intracellular A�46 and the new �-cleavage site may provide a
potential new therapeutic target for the treatment and prevention of AD.
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CHAPER 3
AMYLOID PRECURSOR PROTEIN IS PROCESSED
WITHIN ITS TRANSMEMBRANE DOMAIN BY
SEQUENTIAL E-, �-, AND y-CLEAVAGES
This chapter is about to be submitted by Guojun Zhao et al.
My use of "we" in this chapter refers to my co-authors and myself. I contributed most of
the data and most of the writing.

Abstract
�-amyloid precursor protein (APP) apparently undergoes at least three major cleavages,
y-, e-, and the newly identified s-cleavages, within its transmembrane domain. However,
the roles of e- and s-cleavages in the formation of secreted A� and the relationship of
these three cleavages, namely e-, s-, y-cleavages, remain elusive. We challenged these
issues by attempting to determine the formation and turnover of the intermediates
generated by these cleavages in the presence or absence of the known y-secretase
inhibitors, using a differential inhibition strategy. Our data demonstrate that A�46 is the
direct precursor of secreted A�. Furthermore, our data demonstrate that A�46 is
associated with presenilin in intact cells. We also identified a long A� speciesthat is most
likely the long-sought-after intermediate product, A�49, generated by e-cleavage and this
A�49 is further processed to generate A�46 and ultimately the secreted A�40/42. More
interestingly, our data demonstrate that y-cleavage not only occurs last, but also depends
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on �-cleavage and a-cleavage occurring prior to it. Thus, we conclude that the C-terminus
of secreted A� is generated by a series of sequential cleavages, namely first a-cleavage
followed by �- and y-cleavages.

3.1 Introduction
The mechanism of the formation of the �-amyloid protein (A�) is the central issue in
Alzheimer disease (AD) research, not only because A� is the major constituent of senile
plaques, one of the neuropathological hallmarks in AD, but also because A� formation
may be a causative event in the disease [1]. A� is proteolytically derived from a large
single-transmembrane protein, the �-amyloid precursor protein (APP), as a result of the
sequential cleavages by �- and y-secretases [1]. �-secretase has been identified as a type I
membrane aspartyl protease [72, 73]. Though the exact nature of y-secretase is still a
matter of debate, accumulating evidence supports the ideas that y-secretase is a multiple
molecular complex composed of, at least, presenilins, nicastrin, Aph-1, and Pen-2 and
that presenilin may function as the catalytic subunit [130].
In understanding the mechanism by which the C-terminus of secreted A� is generated
during the processing of APP, three major intramembranous cleavages have been
established. The first one is the cleavage now specifically referred to as y-cleavage [11 O],
which produces the C-termini of most of the secreted A� speciesthat end at amino acids
40 (A�40) or 42 (A�42) of the A� sequence. The second one is the a-cleavage occurring
between A� residues 49 and 50, which produces the N-terminus of most of the APP
intracellular domain (AICD) [109-111, 131]. The identification of this a-cleavage site
raises a question as to whether this a-cleavage is obligatory for the generation of the C-
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terminus of A�, and also raises a question as to the relationship between e- and y
cleavages, whether they are independent of each other or sequential. One of the obstacles
in addressing these questions is that neither the intermediate A� peptide, which ends at
the e-cleavage site, nor the C-terminal fragment, which starts with an N-terminus
generated by y-cleavage, has ever been detected. In a very recent study, we reported the
identification of an intracellular long A� species, A�46. The identification of this long
A�46 led to the discovery of the third cleavage site, the s-cleavage site at A�46 between
the known y- and E-cleavage sites [1 39] .However, the finding that the known y-secretase
inhibitors, such as DAPT and compound E inhibit the formation of secreted A�40/42, and
on the other hand, cause the accumulation of A�46 raises a question as to whether
A�40/42and A�46 are produced by the same enzyme or produced by different enzymes.
Moreover, the roles of E- and l;-cleavages in the formation of secreted A� and the
relationship among these three cleavages, namely e-, l;-, and y-cleavages, also remain
elusive. To address these key issues, the objectives of this study were focused on: (a)
exploring the relationship between A�46 and A�40/42; (b) determining the possible
presence of A�49 generated by E-cleavage and its relationship with A�46 and A�40/42;
(c) examining the possible interaction of presenilin with A�46; (d) elucidating the
relationship of the three major cleavages, the E-, s-, and y-cleavages, within the
transmembrane domain of APP; and (e) establishing the roles of e- and l;-cleavages in the
formation of secreted A�40/42.
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3.2 Materials and Methods
3.2.lMaterials. y-secretase inhibitors, DAPT, DAPM, compound E, L-685,458, and
WPE-III-31C (31C) were from Calbiochem and dissolved in dimethyl sulfoxide. A�40
and A�42 were purchased from American Peptide (California). A�46 and A�49 are
customized peptides.
3.2.2 Cell lines and plasmids. N2a cells stably expressing wild type presenilin 1 (PS1wt)
alone or both PS1wt and Swedish mutant APP (APPsw) were kindly provided by Drs.
Sangram S. Sisodia and Seong-Hun Kim (University of Chicago) and maintained as
described previously [132]. The plasmid APPsw645, which expresses a C-terminal
truncated APP ending at the e-cleavage site A�49, was constructed using the "Site
Directed mutaGenesis Kit" (Stratagene). APPsw [140], which was kindly provided by Dr.
Gopal Thinakaran (the University of Chicago, Chicago), was used as a template and a
pair of oligonucleotides (E49: CGTCATCACCTTGTAGATGCTGAAGAAG; E49-r:
CTTCTTCAGCATCTACAAGGTGATGACG), which are complementary to each other
and contain a stop codon at position 50 of the A� sequence, were used as primers.
3.2.3 Cell-free assay. In vitro turnover of A�46 by y-secretase activity was assayed in a
cell-free assay system established previously [141], following the procedure described in
ref. [109] with minor modifications. Briefly, N2a cells cultured in the absence of
inhibitors were harvested in 9 volumes of homogenization buffer (10 mM MOPS, pH 7.0,
10 mM KCl) containing protease inhibitors (Complete, Roche) and homogenized by
passing through a 20-gauge needle 30 times. After removal of nuclei and cell debris by
centrifugation at 800 x g at 4 °C for 15 min, membranes were pelleted by centrifugation
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at 20,000 x g at 4 °C for 30 min. The membranes were washed once with homogenization
buffer and resuspended in assay buffer ( 1 50 mM sodium citrate pH 6.4, protease inhibitor
cocktail). Aliquots of equal amounts of membranes were then incubated at either 0 °C or
37 °C for the indicated time, in the presence or absence of y-secretase inhibitors. The
reaction was stopped by adding Laemmli SDS sample buffer containing 8 M urea. After
boiling for 5 min, the samples were analyzed by Western blotting.
3.2.4 Immunoprecipitation and Western blotting. Immunoprecipitation and Western

blotting were carried out as described previously[1 39] with the exception that some of
the immunoprecipitation was carried out in the presence of 500 nM DAPT as indicated.
Briefly, 24 hrs after splitting, cells were treated with inhibitors at various concentrations
or as a control, with vehicle only. Eight hrs after treatment, cells were harvested and
lysed in Western blot lysis buffer (50 mM Tris-HCl, pH 6.8, 8 M urea, 5%

P

mercaptoethanol, 2% SDS, and protease inhibitors). Secreted AP was immunoprecipitated
from conditioned media using a monoclonal AP-specific antibody 6El 0 (Senetek). To
immunoprecipitate the intracellular AP species, cells cultured in the presence of DAPT
were lysed with 1 % NP-40 in IP buffer (50 mM Tris/HCl, pH7.4, 1 50 mM NaCl, 0.5%
sodium deoxycholate, 5 mM EDTA, and protease inhibitor cocktail). After centrifugation
at 20,000 x g at 4 °C for 1 5 min, the supernatant was diluted with equal amounts of IP
buffer to lower the concentration of NP-40 to 0.5%. The intracellular AP species were
immunoprecipitated using 6E 1 0. Both cell lysates and the immunoprecipitates were
analyzed by 1 0% Bicine/urea SDS-PAGE or 1 0- 1 8% regular SDS-PAGE and transferred
to a polyvinylidene fluoride membrane (Immobilon-P, Millipore). The membranes were
then probed with specific antibodies and the immunoreactivity bands were visualized
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using ECL-Plus (Amersham Biosciences).
3.2.5 Fractionation and co-immunoprecipitation. In order to determine the formation

of the possible complex of A�46 and presenilin, the following procedure, which was
originally described in a previous study [142] and has been used to partially purify active
y-secretase complex, was employed with slight modification. Briefly, N2a cells
expressing APPsw695/PS1wt cultured in the presence of 3 nM compound E (or 500 nM
L-685,458, Fig. SC) for 10-12 hours were harvested and homogenized in homogenization
buffer A [20 mM HEPES, pH7.4, 50 mM KCl, 2 mM EGTA, 10% glycerol, protease
inhibitor cocktail (Roche)] containing 10 nM compound E (or 2.5 µM L-685,458) by
passing through a 20-gauge needle for 30 times. As illustrated in Fig. 4, the homogenized
samples were subjected to centrifugation at 800 x g for 10 min to separate the unbroken
cells and nuclei and the post nuclear supernatant (PNS). PNS was further centrifuged at
20,000 x g for 1 hour resulting in the supernatant (S 20k x g) and the pellet (P 20k x g).
The resultant pellet, which contains both A�46 and PSl (Fig. 5A), was solubilized in
solubilization buffer B (50 mM PIPES, pH7 .0, 150 mM KCl, 5 mM MgC12, 5 mM CaCh,
and protease inhibitor cocktail) [143] containing 1% CHAPSO and 10 nM compound E
(or 2.5 µM L-685,458), for 1 hour at 4 °C, and then subjected to centrifugation again at
20,000 x g for 25 min to remove the insoluble materials. The supernatant was diluted
with an equal volume of solubilization buffer B to adjust CHAPSO to a final
concentration of 0.5%. After pre-clearing with Protein A sepharose beads for 3 hrs, the
supernatant was incubated with anti-PSlN, a rabbit polyclonal antibody raised against the
N-terminus of PS1[139] in the presence of compound E (or L-685,458) with rotation at
4 °C for 3-4 hours and then an appropriate amount of Protein A sepharose beads was
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added and incubated overnight. As a control, an aliquot of the beads-pre-cleared
supernatant was also incubated with pre-immune serum. After washing twice with
solubilization buffer B containing 0.5% CHAPSO and y-secretase inhibitors and then
twice with PBS, the immunocomplex was eluted with SDS-PAGE Sample loading buffer
and separated by 10-18% SDS-PAGE for A�46 or 10% SDS-PAGE for PSl as described
previously[139]. A�46 and CTF� were detected with 6E10. PSl was detected with anti
PSlL, which recognizes the C-terminus of PSl [144].

3.3 Results
3.3.1 L-685,458 inhibits the formation of Ap46. In our recent study, we have shown

that treatment of cells with non-transition state y-secretase inhibitors, such as DAPT,
DAPM, and compound E caused an increase in the accumulation of intracellular A�46,
indicating that these inhibitors have no or less effect on the newly identified l;-cleavage.
On the other hand, when the cells were cultured in the presence of transition state analogs,
such as L-685,458 and 31C, A�46 was not detectable, strongly suggesting that these
inhibitors inhibit the l;-cleavage and block the formation of A�46 [139] However, it
cannot be ruled out that these inhibitors may fail to block the turnover of A�46, resulting
in A�46 vanishing. To address these issues, N2a cells expressing both PSlwt and APPsw
were treated with DAPT, compound E, and L-685,458, either individually or in
combination. Both cell lysates and the secreted A�40/42immunoprecipitated from
conditioned medium (CM) were analyzed by 10% Bicine/urea-SDS-PAGE as described
previously [135], followed by Western blotting using 6E10. Lane 15 is the mix of
synthetic A�40 and A�42. As shown in Fig. 1, treatment with 0.5 µM DAPT (lane 2) or 5
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nM compound E (lane 3) caused a marked decrease in secreted AP40/42(lower panel)
and a concomitant intracellular accumulation of AP46 (upper panel) as has been shown in
our recent study[1 39]. On the other hand, treatment with L-685,458, at a range of
concentrations from 0.5 to 2.5 µM, completely abolished the formation of secreted
AP40/42in the conditioned medium (CM) (lanes 4-6, lower panel), whereas it did not
cause the accumulation of intracellular AP46 (upper panel). To determine if the absence
of AP46 was a result of the failure of L-685,458 to block the turnover of AP46, cells were
treated with L-685,458 plus 0.5 µM DAPT or plus 5 nM compound E, both of which
have been shown to block the turnover of AP46 [139], and see also lanes 2 and 3, Fig. 1 .
As shown in Fig. 1 , the addition of DAPT (lanes 7 and 8) or compound E (lanes 9 and 10)
did not lead to the accumulation of AP46 in the presence of L-685,458. This result clearly
indicates that the absence of AP46 in cells treated with L-685,458 is due solely to its
inhibition of the formation of AP46, rather than its failure to block the turnover of Ap46.
3.3.2 L-685,458 does not prevent AP46 from turnover. Since the formation of AP46

was blocked in the first place, the experiments described in Fig. 1 did not address the
question as to whether L-685,458 has the ability to block the turnover of AP46, in
addition to inhibiting its formation. To address this issue, a system which contains
preexisting AP46 is required. For this purpose, a cell-free system, which has been
established and used in many previous studies to assay the in vitro y-secretase activity
[109, 141], was employed. Cells were cultured in the absence of any inhibitors; the cell
membranes were prepared, and the cell-free assay was performed in the presence or
absence of inhibitors. As shown in Fig. 2, AP46 was detected in membranes prepared
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from cells cultured in the absence of inhibitors followed by incubation at 0 °C for 1 hr
(lane 1 and lane 5, (lanes5- 1 1 were second batch)). However, when the membranes were
incubated at 3 7 °C for 1 h, A�46 became undetectable (lane 2 and lanes 6, 7), indicating
the quick turnover of A�46 under this condition. Interestingly, when the membranes were
incubated at 37 °C in the presence of either DAPT (lane 3 and 8) or compound E (lane 9),
the amount of A�46 remained largely unchanged, indicating that DAPT and compound E
inhibit the turnover of A�46 in the cell-free system as they do in living cells. However,
when the membranes were incubated at 37 °C in the presence of L-685,458, A�46
became undetectable (lanes 4 and lanes 1 0, 1 1 ). This result clearly indicates that, in
contrast to DAPT and compound E, L-685,458 has no preventative effect on A�46
turnover. Taken together, the data presented in Fig. 1 and Fig. 2 show that L-685,458
specifically inhibits �-cleavage and blocks the formation of A�46, but has no effect on its
turnover. A similar inhibition profile was also observed when 3 1 C was examined (data
not shown).
3.3.3 AP46 is a direct precursor of AIJ40 and AIJ42. As reported in our recent

study[1 39], at the low range of concentrations, DAPM, DAPT, and compound E cause a
dose dependent decrease in secreted AP40/42 and a concomitant increase in AP46 (see
also Fig. 1 ), suggesting a possible precursor-product relationship between AP46 and
AP40/42. This hypothesis is also supported by the facts that AP46 contains the y-cleavage
site at AP40/42and that A�46 is detectable in living cells in the absence of any inhibitors,
suggesting that s-cleavage occurs prior to y-cleavage. However, it cannot be ruled out
that these two cleavages may be unrelated events. The finding that the new s-cleavage
44

can be differentially inhibited by different inhibitors made it possible to determine the
relationship between AJ346 and AJ340/42, and the role of the new �-cleavage in the
formation of secreted A�40/42. As shown in Fig. 3, 24 hrs after splitting, cells were
treated with either 100 nM DAPM (lanes 3 to 5 and 8 to 10; at this concentration DAPM
completely blocks the formation of secreted A�40/42and causes marked accumulation of
AJ346, see Fig. 1) or with the vehicle dimethyl sulfoxide (Me2SO) (lanes 1, 2, 6, and 7)
for 12 hrs. Then, L-685,458 (0.5 µM) was added to the cells in lanes 2 and 7. L-685,458
was also added to the cells in lanes 5 and 10, in addition to the existing DAPM, and
continuously incubated for 40 min to completely stop the generation of new A�46 in
these cells, because at this concentration, L-685,458 blocks the formation of A�46 (Fig.
1). Since L-685,458 has no effect on the turnover of A�46 (Fig. 2), this treatment also
allows the complete turnover of the possibly existing A�46 in cells of lanes 2 and 7.
However, the existing A�46 in cells in lanes 5 and 10, accumulated during the last 12 hrs
of culture, should remain unchanged because of the presence of DAPM, which prevents
the turnover of A�46. As controls, cells in lanes 1 and 6 were untreated. All cells were
then washed twice with fresh cold medium and cultured for an additional 1 hr (lanes 1 to
5) or 2 hr (lanes 6 to 10), either in the presence or in the absence of inhibitors as indicated.
Secreted A�40 and A�42 were immunoprecipitated using 6E10 from CM of the last 1 hr
or 2hr cultures. Both the cell lysates and the secreted A�40/42immunoprecipitated from
CM were analyzed by 10% Bicine/urea-SDS-PAGE followed by Western blotting using
6E10.
As shown in lanes 1 and 6 (lower panel, Fig. 3), secreted A�40/42was detected in cells
cultured in the absence of inhibitors throughout the course of the experiment, and the
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AP40/42is apparently produced in a time-dependent manner during the last 1 hr (lane 1 )
and 2 hrs (lane 6) of culture. As shown in lanes 2 and 7 , CTFP was accumulated in a
time-dependent manner, but neither secreted AP40/42nor intracellular Ap46 was detected
in the cells treated with L-685,458 during the last two incubation periods (40 min and 1
hr or 2 hrs). As shown in lanes 3 and 8, no AP40/42was detected in the CM of cells
treated with DAPM throughout the course of the experiment (lower panel). Instead, a
concurrent accumulation of intracellular AP46 and CTFP was observed in these cells
(upper panel). In contrast, when DAPM was removed during the last 1 hr and 2 hr
incubation, the accumulated AP46 and CTFP were further cleaved to form secreted
AP40/42, in a time-dependent manner (compare lane 9 with lane 4 of both upper and
lower panels). Interestingly, when DAPM was replaced with L685,45 8 during the last 1
hr and 2 hr incubation, the pre-accumulated AP46 decreased (compare lane 1 0 with lane
5, upper panel), and secreted AP40/42concomitantly increased (compare lane 1 0 with
lane 5, lower panel) in a time-dependent manner. It is notable that the accumulated CTFP
remained unchanged (compare lanes 1 0 with lane 5, upper panel). This result indicates
that L-685,458 has no inhibitory effect on the turnover of A(W6 in living cells, which is
in agreement with the result observed in cell-free systems (Fig. 2). The fact that the
accumulated CTFP remains unchanged also indicates that the secreted AP40/42detected
in these cells was solely produced from the pre-accumulated AP46. This conclusion is
also supported by the observation that without pre-accumulating AP46, no secreted
AP40/42was detected in CM of cells cultured in the presence of L-685,458 during the last
1 hr and 2 hrs (lanes 2 and 7). Thus, these results clearly indicate that AP46 is the
precursor of secreted AP40/42. The secreted AP40/42detected in lane 9 is the sum of the
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AP40/42produced from both accumulated AP46 and CTFP, which was most likely
converted to AP46 first, and then the resulting AP46 was further processed to AP40/42.
3.3.4 A p46 is associated with PSl. Previous study has shown that as a substrate of y

secretase, CTFP forms complex with PS1, which is the putative catalytic subunit of the y
secretase complex, at the sites of AP formation [145]. If AP46 is the precursor of
AP40/42, AP46, as an intermediate, may still be associated with y-secretase complex. To
determine whether AP46 is still associated with y-secretase complex, a co
immunoprecipitation experiment was performed as described in the Experimental
Procedures. As illustrated in Fig. 4, lysates of cells treated with compound E were first
subjected to 800 x g centrifugation to remove the unbroken cells and nuclei (P 800 x g).
The resulting post nuclear supernatant (PNS) was subjected to further centrifugation at
20,000 x g resulting in the supernatant (S 20k x g), which contains the microsomal and
cytosolic fractions, and the pellet (P 20k x g), which contains the crude plasma membrane
and trans-Golgi network (TGN)-enriched fraction [146]. As shown in Fig. SA, AP46 was
detected in the unbroken cell fraction of P(800 x g) (lane 1) and the plasma membrane
and trans-Golgi network (TGN)-enriched fraction of P(20k x g) (lane 3), but not in the
fraction of S(20k x g) (lane 2). Interestingly, as shown Fig. 5B, PS I was also detected in
fractions of P(800 x g) (lane 1) and P(20k x g) (lane 3), but not in S(20k x g) (lane 2),
indicating that AP46 co-fractionates with PS I into the 20,000 x g plasma membrane and
TON-enriched fraction. Therefore, as described in the experimental procedure, co
immunoprecipitation was carried out after solublization of the P(20k x g) fraction using
anti-PSlN, an antibody specific to the N-terminus of PSI [139]. As shown in Fig. SC,
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A�46 was indeed co-immunoprecipitated with PSl from the crude TGN-enriched
membranes prepared from cells treated with compound E (lane 2), but not in cells treated
with L-685,458 (lane 6), which inhibits the formation of A�46. In agreement with the
previous study [145], CTF� was also co-immunoprecipitated with PSl (lanes 2 and 6).
The immunoprecipitates were also probed for the presence of PSl using anti-PSlL, an
antibody specific to the C-terminus of PSl [144]. As shown in Fig. 5D, PS l is
immunoprecipitated by anti-PSlN (lane 3) but not by preimmune serum (lane 2),
indicating the specificity of the co-immunoprecipitation.
3.3.5 Detection of the possible Ap49. We also attempted to determine the possible

presence of A�49 generated by e-cleavage. Lysates of cells cultured in the absence of
inhibitor were subjected to immunoprecipitation followed by Western blotting using
6E 10. As shown in Fig. 6A, A�46 was immunoprecipitated from untreated cells (lane 7).
Interestingly, when the immunoprecipitation was carried out in the presence of DAPT, in
addition to A�46, a band with a slower migration rate was detected (lane 8). Possibly due
to the lower concentration and the hydrophobicity, mass spectrometric analysis of this A�
specieswas unsuccessful. To estimate its molecular size, we synthesized two A� peptides,
A�46 and A�49. As it migrates at the same rate as that of the synthetic A�49 (lane 10),
this new A� speciesis most likely the long-sought-after intermediate, A�49, generated by
e-cleavage.
3.3.7 AP49 is the precursor of AP46.To further determine the relationship between

A�49 and A�46, we created a construct, APPsw645, which expresses a C-terminal
truncated APPsw ending at the e-cleavage site A�49. N2a cells, which stably express
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wild type PS 1, were transiently transfected with APPsw645. As expected, AP49 was
detected at a lower concentration (Fig. 6A, lane 4) in the absence of any inhibitors.
Interestingly, two bands were detected when the cells were cultured in the presence of
compound E (Fig. 6A, lane 5). The lower band is apparently the AP46 (compare lane 5
with lanes 7, 8, and 9 of Fig. 6A). This result clearly indicates that AP49 is a precursor of
AP46. Interestingly, when these cells were treated with L-685,458, AP46 was not
detected (lane 6), indicating that L-685,458 blocks the �-cleavage that produces AP46
from AP49. In addition, the fact that the new band detected above the AP46 band in lane
8 migrates at a rate similar to that of recombinant AP49 (lanes 4 to 6) also provides
further evidence supporting that this new AP speciesis the intermediate AP49 generated
by e-cleavage at AP49. It should be noted that under normal conditions, AP49 can only
be detected after enrichment by immunoprecipitation carried out in the presence of DAPT,
indicating its rapid turnover. In the absence of inhibitors, the presence of AP49 in cells
transiently transfected with APPsw645 may be due to the lower efficiency of (-secretase
processing because of the lack of the C-terminal fragment of APP, which may be
required to efficiently interact with y-secretase complex. As shown in lanes 1 to 3 of Fig.
6A, neither AP46 nor AP49 was detected in cells transfected with plasmid pcDNA3. 1 LacZ, which expresses Lacz, regardless of the presence or absence of inhibitors,
indicating that the AP46 and AP49 detected in lanes 4 to 6 are not produced from the
mouse endogenous APP, but are produced from the recombinant APPsw645.
We also endeavored to determine the presence of secreted AP40/42produced by
APPsw645-transfected cells. As shown in Fig. 6B, a band corresponding to AP40 was
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detected in CM of the cells transiently transfected with APPsw645 in the absence of any
inhibitors (lane 2), but not in the cells cultured either in the presence of compound E
(lane 3) or in the presence of L-685,458 (lane 4). This result is in agreement with the
observation that these inhibitors cause intracellular accumulation of AP46 and AP49 (Fig.
6A, lanes 5 and 6). It was noted that the amount of secreted AP40/42produced by the
transiently transfected cells is very low. This is possibly due to the lower efficiency of the
processing of the C-terminal truncated APP expressed by APPsw645. Therefore, we
attempted to establish stable cell lines that stably express this C-terminally truncated APP.
N2a cells, which stably express PSl wt, were transfected with APPsw645. Stable clones
were selected by adding 0418 (for APPsw) and Hygromycin (for presenilin) to the media.
As shown in Fig. 6B, a relatively higher level of secreted AP40/42was detected in the
CM of cells stably transfected with APPsw645 (lanes 5 and 6, shown are two of the
stable clones we selected). In support of our observation, the generation of secreted
AP40/42from the same C-terminal truncated APP mutant was also reported in a very
recent study [147].
3.4 Discussion
By using the combination of L-685,458 and DAPT or compound E, we clearly
demonstrated that the absence of AP46 in cells treated with L-685,458 is not due to its
failure to block the turnover of AP46, but, instead, is due exclusively to its inhibition of
the formation of AP46. In addition, using a cell-free system, our data further demonstrate
that L-685,458 has no effect on the turnover of AP46. A similar inhibition profile was
also observed for 31C (data not shown), indicating that these inhibitors, known as
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transition state analogs, share the same inhibitory specificity, i. e. they specifically inhibit
the formation of A�46 by ('.;-cleavage, but have no effect on the turnover of A�46.
The observation that, under our current experimental condition, L-685,458 has no effect
on the turnover of A�46 is important because this made it possible to determine the
precursor and product relationship between A�46 and A�40/42 in intact cells. Using the
differential inhibition approach, our data, in Fig. 3, clearly reveal the important finding
that AP46 is the direct precursor of secreted AP40/42. This finding indicates that A�46
undergoes further y-cleavage to produce secreted A�40/42.
To further confirm the notion that A�46 is the direct precursor of secreted A�40/42, we
performed the co-immunoprecipitation experiments and found that, as an intermediate
product during the intramembranous processing by y-secretase, A�46 is indeed associated
with PS l. In agreement with the previous study [145], CTF� was also co
immunoprecipitated with PS1 (Fig. 5C, lanes 2 and 6). It was noted that in compound E
treated cells, the amount of CTF� detected in the co-immunoprecipitate is less than that
of A�46. It was also noted that in compound E-treated cells, a significant amount of
A�46 is co-immunoprecipitated with PSl , but A�49 was not detectable. These results
may be explained by the possibility that once bound to presenilin, the initial substrate
CTF� is quickly cleaved at the E-cleavage site and the resulting A�49 is further and
rapidly cleaved at the c'.;-cleavage site leading to the formation of A�46. The lower
amount of the residue A�49 was not detectable under our current co-immunoprecipitation
experimental condition. In the presence of compound E, the cleavage at y-cleavage site is
inhibited and results in the accumulation of A�46. The accumulated A�46 occupies the
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binding site of the y-secretase complex and prevents the further binding of CTF� to the y
secretase complex, resulting in the accumulation of CTF� (Fig. 1, lanes 11 to 14).
However, most of the accumulated CTF� is not associated with PS1 and is detected in the
fraction containing the microsomes and cytosol, which are free of PS1 (Fig. 5A, lane 2).
Taken together, these results indicate that once bound to presenilin, the initial substrate,
CTF�, and the intermediate product, A�46, are closely associated with presenilin until the
release of the final product of secreted A�40/42. Thus, all the data presented support our
hypothesis that secreted A�40/42is produced from APP by a series of sequential
cleavages by y-secretase, i.e. e-cleavage at A�49, �-cleavage at A�46, and y-cleavage at
A�40/42.
The fact that L-685,458 and 31C have no effect on the turnover of A�46 (Fig. 2) and the
facts that these inhibitors block the formation of A�46 from A�49 by s-cleavage (Fig. 6A)
and that these inhibitors block the formation of AICD by E-cleavage [110, 111] indicate
that transition state analogs L-685,458 and 31C specifically inhibit E- and �-cleavages,
but have no effect on y-cleavage. The finding that L-685,458 and 31C do not directly
inhibit y-cleavage strongly supports an important notion that these inhibitors inhibit the
formation of secreted A�40/42in living cells by a mechanism other than direct inhibition
of y-cleavage, but indirectly, by inhibiting the formation of A�46. This idea is supported
by the fact that A�46 is detectable in cells cultured in the absence of any inhibitor,
indicating that �-cleavage must occur prior to y-cleavage, i. e. �-cleavage is upstream of
y-cleavage. Therefore, the finding that inhibition of upstream e;-cleavage by L-685,458
and 31C completely prevents the downstream y-cleavage from taking place strongly
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supports an important notion that, in living cells, y-cleavage not only occurs secondarily,
but also is dependent on s-cleavage occurring first. In this regard, the fact that the
putative AP49, which contains the s-cleavage site at AP46, is detectable in living cells in
the absence of any inhibitors (lane 8, Fig. 6A) indicates that e-cleavage occurs prior to s
cleavage, otherwise the E-cleavage product AP49 should not have had a chance of being
formed. Moreover, our data clearly demonstrated that L-685,458, which does not directly
inhibit y-cleavage, also blocked the formation of secreted AP40/42from AP49 produced
from the truncated APP mutant APP645 (Fig. 6B, lane 4), indicating that secreted
AP40/42 cannot be directly formed from AP49 without the formation of the intermediate
AP46 by s-cleavage. Thus, as illustrated in Fig. 7, our data strongly suggest that after P
or a-cleavage of APP, the resulting CTFP and CTFa first undergo e-cleavage, followed
by a sequential but rapid s-cleavage and then a y-cleavage, commencing at the site closest
to the membrane boundary and proceeding towards the site within the middle of the
transmembrane domain of APP. More importantly, y-cleavage not only occurs last, but
also is dependent on E- and s-cleavages occurring prior to it. Accordingly, our data
establish that the e-cleavage is not only an obligatory step, but also the initial step of the
sequential s-,

s-, and y-cleavages involved in the generation of the C-termini of secreted

Ap .
The finding that

E-

and s-cleavages and y-cleavage can be differentially inhibited by

transition state analogs and non-transition state inhibitors respectively, suggests several
possibilities. First, these cleavages may be catalyzed by two enzymes and second, these
cleavages may be catalyzed by one enzyme which has two inhibitor binding sites, one for
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the transition state analogs, such as L-685,458, and the other for the non-transition state
inhibitors, such as compound E, as suggested by a recent inhibitor binding kinetic study
[ 148]. The sequential relationship of these cleavages and specifically the finding that y
cleavage is dependent on s- and �-cleavages occurring first strongly suggest that y-, c;-,
and £-cleavages are catalyzed by a single enzyme. According to this model and the
hypothesis described in ref. [148], the transition state analogs inhibit the initial cleavage,
namely the £-cleavage, by directly binding to the catalytic site. As a result, the
downstream c;- and y-cleavages are also prevented from taking place. On the other hand,
the non-transition state inhibitors may bind to a remote site of the enzyme and induce
conformational changes on the enzyme, resulting in the preferential inhibition of y
cleavage with less effect on the E- and c;-cleavages by preventing the y-cleavage site from
accessing the catalytic site of the enzyme. However, the one catalytic site model fails to
account for the fact that AP46 is still processed to AP40/42by y-cleavage in the presence
of the transition state analogs (Fig. 3), which is assumed to bind the catalytic site [ 148].
Therefore, the third possibility is likely that these sequential cleavages may be catalyzed
by an enzyme which has two catalytic sites. Regardless of one or two catalytic sites,
according to the one enzyme model, at high concentrations the non-transition state
inhibitors, which preferentially inhibit y-cleavage, may also inhibit E- and c;-cleavages by
an allosteric mechanism, i. e. these compounds may introduce conformational changes
into the y-secretase complex, resulting in partial inhibition of s- and c;-cleavages. The one
enzyme model is also supported by the fact that both groups of the inhibitors have been
shown to bind to presenilins [88, 1 49, 1 50].
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CHAPTER 4
CHARACTERIZATION OF y-SECRETASE
INHIBITORS: THEIR EFFECTS ON AfJ46
ACCUMULATION AND TURNOVER
This chapter is about to be submitted by Guojun Zhao et al.
My use of "we" in this chapter refers to my co-authors and myself. I contributed most of
the data and most of the writing.

Abstract
Accumulation of AP, including intracellular AP, has been thought to play an early and
crucial role in the pathogenesis of Alzheimer's disease. Inhibition of y-secretase is one of
the promising therapeutic strategies to slow disease progression. Structurally diverse y
secretase inhibitors have been demonstrated to abolish AP production both in cultured
cells and in mouse models. However, most recently we demonstrated that application of
some y-secretase inhibitors led to accumulation of intracellular AP46, which could be
toxic to neurons. Here we have examined various y-secretase inhibitors regarding their
effects on intracellular AP46 accumulation as well as AP46 turnover. We found that
NSAID y-secretase inhibitors ibuprofen and sulindac sulfide, and isocoumarin based
inhibitor JLK6 did not lead to accumulation of intracellular AP46 or CTFP. On the
contrary, high dose of NSAIDs blocked the endogenous level of AP46. Two new classes
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of y secretase inhibitors, peptide aldehyde Z-Leu-Phe-CHO and fenchylamine
sulfonamide based inhibitor (inhibitor VI) exhibited DAPT-like effect, leading to
intracellular accumulation of both A�46 and CTF�, whereas peptide aldehyde 2Naphthoyl-VF-CHO displayed transition state analogue-like effects, accumulating CTF�
without A�46. By examining the turnover rate of pre-accumulated A�46 after removal of
y-secretase inhibitor, we observed that benzodiazepine containing inhibitors displayed the
strongest inhibitory stability. In the presence of L685,458, pre-accumulated A�46 was
turned over into A�40 and A�42, while in the presence of 3 1 C, A�46 was processed into
A�43 and a longer A� species. Taken together, our data provide new insights into the
understanding of various y-secretase inhibitors.

4.1 Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized
pathologically by extracellular amyloid plaques, intracellular neurofibrillary tangles, and
loss of neurons in the cerebral cortex[! ] . According to the amyloid cascade hypothesis,
the accumulation of �- amyloid protein (A�) plays an early and causal role in the
pathogenesis of AD[12, 32, 1 38]. The primary components of amyloid plaques are
heterogeneous A� species, predominantly A�40/42 [8- 1 O] . A�40 is the major species
generated from cells, whereas the slightly longer and less abundant form of A�42 is more
hydrophobic, more prone to aggregation, and more pathogenic[l O]. A� peptides are
generated from �-amyloid precursor protein (APP) by sequential actions of �- and y
secretases.
y-secretase has been shown to cleave APP in its transmembrane domain at two sites: the
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y-site at A�40 or A�42 generating A�40/42, and the E-site at A�49 releasing APP
intracellular domain (AICD) [109-111]. Most recently we identified another major y
secretase cleavage site, the �-site, at A�46 in the transmembrane domain of APP[139]. In
addition, y-secretase has also been identified to cleave several other type I
transmembrane proteins such as Notch[99, 121], Erb4[100], CD44[103], E-cadherin[102],
APLPl and APLP2[101]. However it is currently unclear whether these cleavages are
occured through the same or similar but slightly different mechanisms. This is an
important issue for the therapeutic approaches to inhibit y-secretase activity.
Inhibition of A� generation by targeting either �- or y-secretases is one of the promising
therapeutic strategies to prevent AD. However, it has been proven difficult to design
small drug-like molecular inhibitors for �-secretase[l51, 152]. Inhibition of y-secretase
has also been hampered by the diverse substrates of y-secretase. Early y-secretase
inhibitors were peptide aldehydes [153], or substrate based difluoroketones[154] and
difluoro alcohols [155], which are generally weak inhibitors.

Compound library

screening and subsequent chemical optimization led to the developments of some potent
semi-peptide inhibitors such as DAPT[156], compound E [150] and transition state
analogues such as hydroxyethylene dipeptide

isostere (L685,458) [157], and

hydroxyethyl urea based 31C [149]. Although structurally diverse y-secretase inhibitors
have been shown to effectively decrease A� level in cultured cells as well as in mouse
models of AD[158, 159], most of these inhibitors also block other y-secretase mediated
cleavages in addition to APP[l60]. Isocoumarin based inhibitor JLK6 has been reported
to selectively reduce A� secretion without affecting other y-secretase mediated cleavages
[113]. However it failed to block solubilized y-secretase activity, indicating that it did
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not act at the y-secretase level[114]. Recently, a subset of NSAIDs, such as ibuprofen,
and sulindac sulfide, have been found to selectively lower AP42 level without affecting
AP40 and ACID generation [115]. However the mechanism by which NSAID drugs
specifically inhibit AP42 generation has not been well defined.
Most recently, we dissected APP transmembrane cleavages into three steps, and found
that some y-secretase inhibitors at certain concentrations preferentially blocked y-site
cleavage,

causing intracellular accumulation of AP46[139].

Intracellular AP

accumulation has long been speculated to play an early and important role in the
pathogenesis of AD[161-163]. Growing evidence has demonstrated the cytotoxicity of
intracellular AP [32, 164, 165]. It is of great importance to examine whether any other y
secretase inhibitors could affect intracellular AP levels. Here we screened available y
secretase inhibitors to assess their effects on AP46 accumulation as well as AP secretion.

4.2 Materials and Methods
4.2.1 Materials. y-secretase inhibitors were all purchased from Calbiochem, and

dissolved in dimethylsulfoxide (Me2 SO). Monoclonal antibodies 22Cl 1 and 6E l0, which
recognize residues 66-81 of APP and residues 1-1 7 of the AP sequence, respectively,
were from Boehringer Mannheim and Senetek, respectively. Polyclonal antibody C15
raised against the C-terminal 15 residues of human APP has been described before [139].
HRP conjugated anti-rabbit and anti-mouse antibodies, Protein-A agarose beads, and
ECL-Plus western blotting system were all obtained from Amersham Biosciences.
4.2.2 Cell culture and inhibitor treatment. A mouse neuroblastoma cell line stably

expressing Swedish mutant APP695 and human wild-type PS1 (N2aAPPsw695/PS1wt)
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was established as described previously [1 32]. Cells were grown in Dulbecco' s modified
Eagle' s medium plus 1 0% fetal bovine serum for 24h. Then media were replaced with
fresh media containing either Me2SO as a control or appropriate y-secretase inhibitors at
the concentrations listed in Table 1 . After incubation of cells with inhibitor for 1 0 h,
conditioned media (CM) were collected and centrifuged at 3000x g for 1 0 min to remove
cell debris. Cells were collected in Lysis buffer(50mM Tris-HCl, pH6.8, 2%SDS, 8M
urea, 2mMEDTA, 2mM DTT, and protease inhibitor cocktail ) with a rubber policeman
on ice as described previously[1 39] . After brief sonication, lysates were mixed with SDS
PAGE sample loading buffer and boiled for 5 min before loading. For the pre
accumulated AP46 turnover assay, N2aAPPsw/PS 1 wt cells were grown in the presence of
DAPM (Fig5) or other inhibitors as indicated (Fig4) for 1 2 h to accumulate AP46, then
media were removed and cells were washed with cold media twice. Fresh media with or
without inhibitor as indicated in each figure were added and the cells were further
cultured for 2h before harvesting both the conditioned media and cells for analysis.
Appropriate y-secretase inhibitors were contained in wash media as indicated in figure
legends.
4.2.3 Immunoprecipitation of AP from conditioned media. Immunoprecipitation of
secreted AP from conditioned media was carried out as described previously[1 39] .
Briefly, centrifuged conditioned media were incubated with 6E 1 0 antibody for 3 h at 4° C
followed by addition of protein-A conjugated agarose beads. After overnight incubation
at 4 ° C with shaking, the resulting immunocomplex-protein-A beads were collected by
centrifugation at 5000x g and washed with 1 X PBS three times before adding SD S
pAGE sample loading buffer and denaturing at 1 00° C for 5min.
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4.2.4 Western blotting. Western blotting was performed as described previously [1 39].
For detection of soluble APP from conditioned media, samples were run on 8% SDS
PAGE Tris-glycine gels, transferred to polyvinylidene difluoride membranes, and probed
with 22C 1 1 or 6E 10 antibodies. For analysis of intracellular A� speciesand APP
fragments, samples from cell lysates were separated on a 1 0%- 1 8% two-step Tris-glycine
SDS-PAGE system, transferred to polyvinylidene difluoride membranes, and probed with
either 6E 1 0 or C 1 5 antibody. For detection of secreted A� species, immunoprecipitated
samples were run on freshly made a 10% Bicine/Urea SDS-PAGE system, transferred to
polyvinylidene difluoride membranes, and probed with 6E 1 0 antibody. All primary
antibodies were incubated overnight and secondary antibodies incubated for 1 h. Bands
were visualized with the ECL-plus system (Amersham Biosciences).

4.3 Results
4.3.1. Ibuprofen and Sulindac sulfide do not elevate intracellular AP46 level. The
finding that some nontransition state analogues caused intracellular accumulation of
A�46 prompted us to examine other available y-secretase inhibitors. Recently, subsets of
NSAIDs, such as ibuprofen and sulindac sulfide, have been described to specifically
block A�42 generation. To examine whether these NSAIDs affect intracellular A�46
level, we cultured N2a APPsw/PS 1 wt cells, which stably express Swedish mutant
APP695 plus human wild-type PS 1 , in the presence of either ibuprofen, sulindac sulfide,
DAPT or compound E (as positive control) for 1 0 h. As expected, DAPT and compound
E treatment led to intracellular accumulation of A�46, as detected with 6E 1 0 from cell
lysates( Fig lA, lanes 2-5). In contrast to DAPT or compound E treatment, we did not
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observe an elevated level of A�46 in the lysates from either ibuprofen or sulindac sulfide
treated cells (Figl A. top panel, Lanes6-8). On the contrary, 500µM ibuprofen and 60µM
sulindac sulfide decreased endogenous level of A�46 (Fig lA, bottom panel, longer
exposure, compare lanes 7 and 8 with lane1).

Consistent with results from 6E10

detection, no increased C-termini of APP were found from ibuprofen and sulindac sulfide
treated cells when probed with C l 5 antibody (FiglB. compare Lanes6-8with lane 1).
These results indicate that NSAIDs inhibit y-secretase through a mechanism distinct from
that of DAPT. Indeed, NSAIDs have been shown to modulate rather than inhibit y
secretase by switching the cutting site from A�42 to A�38[115], which may account for
the lack of increase of intracellular A�46 level. Inhibition of endogenous level of A�46
by high concentration of ibuprofen and sulindac sulfide may be caused by nonspecific
inhibition, since at this concentration A�40 level was also slightly reduced (Fig2C,
compare lanes 18 and 19 with lane10).
4.3.2. Peptide aldehydes and sulfonamide based inhibitors elevate intracellular AIJ46
level. To explore the effects of other y-secretase inhibitors on intracellular A�46 level, we

cultured N2aAPPsw/PS1wt cells in the presence of various y-secretase inhibitors and
examined their inhibition profiles. In addition to DAPT, DAPM, and CPDE, which have
previously been found by us to increase A�46 level, we found two heavy bands in 1-(S)
endo-N-( l ,3,3

trimethylbicyclo[2.2. l]

hept-2-yl)-4-fluorophenyl

sulfonamide

(inhibitorVI)[l 66] treated lysate (Fig2A, top panel lane6). The two bands are most likely
CTF� and A�46, respectively, as they ran at the same migration rates as those of DAPT
treated samples in both 10-18% SDS-PAGE( Fig2A, top panel, lanes 6 and 7, for CTF�
also see Fig2A, bottom panel, lanes 6 and 7) and 10% Bicine/Urea SDS-PAGE
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system( data not shown), respectively. This finding indicates that in addition to
peptidomimetic inhibitors such as DAPT, DAPM and Compound E, fenchylamine
sulfonamide based y-secretase inhibitor also causes increase of intracellular AP46 level. It
was noted that although inhibitor VI decreased AP40 secretion, it did not alter secreted
AP42 level (Fig2C, compare lane 6 with lane 1 ). Since AP40 and 42 have been described
as generated in different cellular compartments [1 67], variation in the ability of this
inhibitor to reach different compartments may account for the decreased inhibitory effect
on AP42.
Application of peptide aldehyde inhibitor, N-benzyloxycarbonyl-Leu-phenylalaninal
(inhibitor V, or Z-Leu-Phe-CHO)[1 68], also led to accumulation of both AP46 (Fig2A,
top panel lane5), and CTFP (Fig2A, bottom panel, lane5), though to a lesser extent when
compared with DAPT treatment (Fig2A, both panels in lane5). Interestingly, although
both AP46 and CTFP increased, treatment of inhibitor V at 25 µM did not block AP
secretion, but rather dramatically elevated AP42 level and slightly increased AP40
(compare Lane 5 with Lane 1 in Fig2C), which is most likely due to the inhibition of non
secretase-mediated degradation of CTFP[l 53, 1 68] . In addition, it has been believed that
not all CTFP undergoes secretase-mediated proteolysis, but rather is degraded[ l 69].
We also found that treatment of naphthoyl-Val-Phe-CHO (Z-Val-Phe-CHO, or inhibitor
IV) caused dramatic increase of CTFP, but not AP46 (Fig2A, lane 4 in both panels),
which is very similar to the L685, 458 and 3 1 C induced effect (Fig2A, lanes 8 and 1 5, in
both panels). Z-Val-Phe-CHO was originally identified as a potent cystein protease
inhibitor[l 70] . It has also been shown to inhibit AP release in a dose dependent manner
[1 53]. Consistent with this previous finding, we observed a strong inhibition of AP
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release (Fig2C, Compare lane 4 with lanel). Z-Val-Phe-CHO is not transition state
analogue. If it inhibits y-, �-, and e-cleavages at equal potency, we should see either some
longer AP species such as AP46 and AP49, or some CTFy and CTF�, in addition to CTFe.
Failure to detect other AP and C-terminal fragments in addition to CTFP suggests that Z
Val-Phe-CHO preferentially blocks the first cleavage among y-, �-, and e-sites, and
cleavages of APP at its TM domain are sequential events.
Other peptide aldehyde inhibitors such as y40-I, y40-II, and XIV, did not exhibit
significant accumulation of either AP46 or CTFP (Fig2A, lanes 2, 3, and 1 2). Inhibitors
XII, and XIII caused a slight accumulation of CTFP and even less amount of AP46
(Fig2A, lanesl0 and 1 1 ), presumably due to low dose of inhibitor. However, increasing
concentration of these inhibitors resulted in a toxic effect as evidenced by cellular
morphology change. Peptide aldehyde inhibitors have been reported to exhibit poor
specificity[l 71], and this may explain why y40-I and XIV did not lead to accumulation
of CTFs or Ap46 despite the reduced AP secretion(Fig2C lanes2 and 1 4).
For the isocoumarin derivative, although JLK6 moderately inhibited secretion of AP40
and 42(Fig2C, compare lanel 1 with lanelO), no concomitant increase in the levels of
CTFs was found (Fig2A and B lane9). Further increasing the JLK6 concentration resulted
in cytotoxicity in N2a cells. Previous observation suggested that JLK6 does not directly
act on y-secretase, which may also account for the absence of elevated AP46 or
CTFP[1 1 4].
4.3.3 Inhibitor VI and 31C selectively abolish AP40 secretion. Having noticed that

inhibitor V and VI selectively inhibit accumulation of AP40 over AP42, we adjusted the
inhibitor concentrations to test whether other inhibitors could also display this effect. For
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inhibitor V, no inhibitory effect was found at Sµm (Fig3A, lane4). Since we have
observed enhanced secretion of A�42 at 25µm (Fig2C lane5), we increased the
concentration to 75µm, however, this concentration led to some cytotoxic effects as
noticed by cell morphology change. Interestingly, even at this high concentration, it still
preferentially blocked A�40 over A�42 (Fig3B, lanes, longer exposure). Inhibitor VI
preferentially blocked A�40 generation at 20µM (Fig3A, lane?), however, lower
concentration did not elevate A�42 level (Fig3A, lane6). The transition state analogue
31C specifically enhanced A�42 release at lower concentration (Fig3A, lane15), and had
less effect on A�42 than on A�40 (Fig3A, lane15) at higher concentration. The other
selected inhibitors, including another transition state analogue, L685,458, (Fig3A,lanesl 1
and 12) did not exhibit preferential inhibition with respect to A�40 and A�42.
Structurally diverse inhibitors including peptide aldehyde (inhibitorV), sulfonamind
(inhibitor VI), and hydroxyethyl urea (31C) displayed preferential inhibition possibly via
different mechanisms such as inhibitor accessibility, blocking nonspecific degradation,
and allosteric effect.
4.3.4. Benzodiazepine containing inhibitors form the most stable complex with y
secretase. Several inhibitors have been demonstrated to bind to y-secretase in a

noncompetitive manner with substrate[148]. To assess the binding stability of inhibitor-y
secretase complex, we first cultured cells in the presence of y-secretase inhibitors for 12 h,
then removed inhibitors by washing with cold fresh medium twice, followed by adding
fresh media without any inhibitor (for each corresponding control, fresh media with
corresponding inhibitor), and incubated the cells for 2h. We found that removal of
inhibitors IV, VI, XVI, and 31C (XVII) led to elevated level of A� ( Fig4, top panel,
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lanes 3,7, 14,16, respectively), with concomitant disappearance of pre-accumulated CTF�
and A�46( Fig4,bottom panel, compare lanes3,7,14, and 16 with lanes 2,6, 13, and 15,
respectively), suggesting that the binding of these inhibitor with y-secretase is unstable.
In contrast to the above results, pre-accumulated A�46 in lysates from inhibitor XVIII
(compound E) and XIX treated cells remained largely unchanged(Fig4, lower panel,
compare lanes18 and 20 to lanes 1 7 and 19), which suggests stable binding between these
two inhibitors and y-secretase. Both inhibitor compound E and inhibitor XIX are
benzodiazepine based drugs, and their structure may contribute to the strong binding.
Indeed these two benzodiazepine derivatives exhibited the lowest IC50 for A� generation.
4.3.5. L685, 458 and 31C differentially affect y-secretase specificity. Both L685,458

(inhibitorX) and 31C(inhibitor XVII) are aspartyl protease transition state analogues.
They both diminished A� secretion and concomitantly led to accumulation of CTF�.
Since L685,458 has been shown to display no inhibitory effect on A�46 turnover ( chapter
3), we attempted to examine whether and how 31 C affects pre-accumulated A�46
turnover. To accumulate A�46, cells were cultured in the presence of DAPM for 12h,
then the media were removed and cells were washed with cold fresh medium twice. To
block full length APP and CTF� processing into A�40/42, we employed L685,458, and
31 C, which both strongly inhibit A� generation from CTF�. Appropriate controls such as
without pre-accumulation of A�46 and continuous incubation with DAPM and L685,458
were also included. Thirty-five min pretreatment for L685,458 and 31C was performed
before washing step to allow these inhibitors to enter cells. Appropriate 'Y secretase
inhibitors as listed in the figure were included in washing media. After wash, fresh media
with or without L685, 458 or 31 C were added followed by incubation for 2h before
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harvesting conditioned media and cells. As shown in Fig 5 lanes 2, 3 and 6 to 9, both
L685,458 and 31C blocked CTF� turnover, but failed to inhibit A�46 turnover (Fig5 top
panel, compare lanes 6 , 8 and 9 with lane4). Concomitantly, A�40 and A�42 bands
were observed in samples from DAPM pre-treated cells subsequently cultured in the
presence of either L685,458 alone or L685,458 plus Z-VAD (Fig5, lower panel, lanes 6
and

9), but not in the samples from L685,458 treated cells without DAPM

pretreatment(Fig5, bottom panel,lane2), indicating that L685,458 did not affect A�46
turnover intoA�40and A�42 under the test conditions. Adding Z-VAD to the medium did
not block A�6 turnover (compare lane 9 to lane 6, in both panel), which excludes the
possibility that A�46 was turned into Abea40/42 via caspases activity. Intriguingly, two
A� bands with faster mobility than those of A�40/42were found in the sample from
DAPM pre-treated and subsequently 31C treated cells(Fig5, bottom panel, lane 8) but not
from cells treated with 31C without DAPM pre-treatment (Fig5,lower panel, lane3),
indicating that the two A� species were derived from A�46 in the presence of 31C. Due
to the lower amount, the identities of these two A� species have not been determined by
mass spectrometry analysis. However, these two bands ran faster than A�40 and 42 in
this Bicine/Urea SDS-PAGE system, suggesting that they contain more hydrophobic
residues. As both 31C and DAPM do not alter �- or a-secretases specificity, these bands
must start from first residue of A�. Thus, the major band is likely A�43 (Fig5, lower
panel, lane8, upper band) as A�43 runs slightly faster than A�42 in this separation
system [139]. The lower band in Fig 5 lane 8 is between A�44 and A�46. Similar results
were obtained when using inhibitor VI to pre-accumulate A�6, whereas co-incubation of
31C either with DAPM or with inhibitor VI abolished any A� secretion (data not shown).
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The reason why AP46 turnover into AP40and 42 was seen in the presence of L685,458,
whereas turnover into AP43 and 44/45/46 in the presence of 31 C was seen is not clear at
present. Inhibitor structure difference could account for the discrepancy in AP46 turnover.
Binding of 31C to y-secretase may induce conformational change which alters y-secretase
specificity, inhibiting y-secretase cleavage at 40 and 42 sites but favoring cleavages at 43
and 44/45 sites, whereas the conformation change introduced by binding of L685,458
differs from that induced by 31C, as the structures of 31 C and L685,458 are different.
Indeed 31 C exhibited a less inhibitory effect on AP42 than on AP40 (Fig3A, lanes15 and
16), while L685,458 displayed an equal effect on both AP40 and AP42 (Fig3A, lanes 11
and 12) secretion.

4.4. Discussion
Accumulation of AP is thought to be the central event in the pathogenesis of AD.
Targeting y-secretase is one of the potential therapeutic strategies in seeking to slow
disease progression. Structurally diverse y-secretase inhibitors have been shown to
diminish AP generation both in cells and in mouse models. Most recently, we have
demonstrated that treatment of cells with some semipeptide inhibitors such as DAPT,
DAPM, or compound E elevated intracellular AP46 levels, whereas application of some
transition state analogues including L685,458 and 31C led to accumulation of CTF�
without AP46. Growing evidence has demonstrated that accumulation of intracellular
A�42is toxic to neurons [164, 165]. It is conceivable that the longer and more
hydrophobic AP46 could be more toxic to neurons than AP42. Thus it is necessary to re
evaluate available y-secretase inhibitors with respect to their effects on intracellular AP
speciesand CTFs, which is not only important for secretase inhibitor design, but also
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facilitates understanding the underlying mechanism of y-secretase mediated cleavages.
For the present study we screened available y-secretase inhibitors to examine whether and
how these compounds could affect intracellular A�46 formation as well as A�46 turnover.
Here we found that two NSAIDs (ibuprofen, sulindac acid), one isocoumarin derivative
(JLK6), and some peptide aldehydes (y40-I, y40-II, XIV) did not increase accumulation
of A�46 or CTF�. On the contrary, high concentration of ibuprofen and sulindac sulfide
abolished endogenous level of A�46. Both ibuprofen and sulindac sulfide have been
demonstrated to specifically block A�42 release without affecting A�40 and e-cleavage.
It has been suggested that these NSAIDs modulate y-secretase specificity, switching the
cleavage site from A�42 to A�3 8, but largely do not affect A�40 cleavage [1 1 5].
Consistent with these previous observations, our result shows that these two NSAIDs
exhibited distinct effects from those of peptidomimetic inhibitors and transition state
analogues with respect to A�46 and CTF� accumulation. As intracellular A� species has
been believed to be toxic to cells, reduction of A�42 secretion by some NSAIDs without
increased intracellular A� species is of great significance for their potential therapeutic
applications. JLK6 has been described selectively inhibiting A� release without affecting
e-cleavage[l 1 3], however the mechanism remains unclear. Subsequent study has shown
that JLK6 does not directly act at the y-secretase level[1 1 4], which could account for the
failure to detect elevated level of A�46 or CTF�. The reason why some peptide aldehyde
inhibitors did not cause dramatic accumulation of A�46 and CTF� is most likely that they
are weak inhibitors with low specificity. Due to nonspecific inhibition, increasing
concentration leads to cytotoxic effects, resulting in low A� secretion. Thus reduction in
A� level does not cause significant accumulation of A�46 or CTF�.
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Our previous studies have demonstrated that peptidomimetic and benzodiazepine
containing inhibitors cause intracellular accumulation of both AP46 and CTFP. Here we
report that two new classes of inhibitor, a fenchylamine sulfonamide containing inhibitor
(inhibitor VI), and a peptide aldehyde inhibitor (inhibitor V). Both exhibited effects
similar to that of DAPT and compound E, although the aldehyde inhibitor displayed less
potency. The observation that structurally diverse inhibitors display similar effects with
respect to accumulation of intracellular AP46 strongly supports our previous finding that
�-cleavage is a physiological event closely related to y-site cleavage. Intriguingly, another
peptide aldehyde, inhibitor IV (2-Naphthoyl-VF-CHO), mainly caused accumulation of
CTFP without accumulation of AP46, a result very similar to that produced by transition
state analogues. If inhibitor IV blocks y- , �- and e-sites cleavages with equal potency, we
should see some intracellular AP speciessuch as AP46 and AP49, at least at low
concentration. The failure to see AP46 and AP49 suggests that APP C-terminal cleavages
are not random, but rather sequential actions. Inhibitor IV most likely blocks the initial
cutting site, thus leading to accumulation of CTFP alone.
Among the tested inhibitors, inhibitor V, VI, and 31C showed less potency for AP42 than
AP40. In particularly, inhibitor V and 3 1 C specifically elevated AP42 level at certain
concentrations. Several factors could account for these results. First, binding of inhibitor
to y-secretase induces conformational change, which may favor AP42 cleavage. Second,
inhibitor accessibility may confine inhibitory effects to certain subcellular compartments
where AP40 is generated, as AP40 and AP42 have been suggested to be generated in
different compartments [ 1 67] . Third, moderate inhibition of AP40 cleavage at low
inhibitor concentration leaves more substrates for AP42 cleavage, resulting in more AP42.
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Finally, blocking nonspecific degradation may also contribute to the increase of A�42,
since not all CTF� undergoes secretase mediated proteolysis[ 1 69] . It is conceivable that
these factors may coexist in some cases.
Several inhibitors have been demonstrated to bind to y-secretase in a non-competitive
manner [148]. In the present study, we analyzed inhibitor-y-secretase complex stability
after removal of inhibitor from medium by evaluating the turnover of pre-accumulated
A�46 and CTF�. We found benzodiazepine-containing inhibitors displayed the strongest
inhibitory stability. Inhibitor-y-secretase complex stability should depend on inhibitor
concentration, binding affinity, and binding manner. Since the concentration of
benzodiazepine containing inhibitors is the lowest among tested inhibitors, their strong
binding comes from either high affinity or stable chemical bonds between inhibitor and y
secretase.
Although both L685,45 8 and 3 1 C are transition state analogues, which are believed to
bind to the active site of y-secretase leading to accumulation of CTF�, differences
between L685,458 and 3 1 C have been noted in this study. First, L685,458 equally
blocked both A�40 and A�42 generation while 3 1 C displayed less potency for A�42 than
for A�40. Second, A�46 was converted into A�40 and A�42 in the presence of L685,458,
whereas it was processed into A�43 and a longer A� species in the presence of 3 1 C. The
reason for these discrepancies is not clear at present. One possible explanation is that
binding of hydroxyethylene dipeptide isostere L685,458 to the active site of y-secretase
may do not affect y-secretase specificity, whereas binding of (hydroxyethyl) urea based
3 1 C to the active site of y-secretase most likely introduces a conformational change,
which alters y-secretase specificity.
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Taken together, our data provide new insights into the understating of various secretase
inhibitors. Previous y-secretase screenings were focused on their effects on A� secretion
as well as on e- and S3-site cleavages in the Notch signal pathway. As most tested y
secretase inhibitors lead to either accumulation of CTF�, or CTF� plus A�46, which is
believed to be toxic, further work on y-secretase inhibitors should also consider
intracellular A� species.
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CHAPTER S
Ap46 IS GENERATED IN THE GOLGI/ TRANS
GOLGI NETWORK IN NEURO 2A CELLS
This chapter is about to be submitted by Ouojun Zhao et al.
My use of "we" in this chapter refers to my co-authors and myself. I contributed most of
the data and most of the writing.

Abstract
Subcellular sites for generation of A� have been the subject of intensive research.
Different A� species are know to be generated in distinct subcellular compartments. We
previously identified a novel cleavage, the �-site, in the transmembrane region of �
amyloid precursor protein. Here we report that A�46 is generated in the Oolgi/trans
Oolgi-network (TON) compartments in neruo 2a cells. Using brief centrifugation, we
found that A�46 was present in 20,000 x g membrane fraction but not in 20,000 x g
supernatant. Cell surface trypsinization demonstrates that the majority of AP46 is
resistant to trypsinization. Treatment with brefeldin A (BFA) completely abolished AP46
generation, whereas monensin only exhibited inhibitory effect on AP46 generation at
high concentrations, suggesting that A�46 is generated in the Oolgi and TON. In addition,
neither 25mM NH4Cl nor 1OµM lactacystin affected A�46 level, indicating that A�46 is
less likely generated in endosomes/lysosomes, and preteasomes. Furthermore, addition of
an ER sorting signal to the C-terminus of APP diminished A�46 and A�40/42generation,
whereas retention of APP in the TON with a TON sorting motif did not after A�46 or

72

AP40/42level, confirming that AP46 is generated in the Golgi/TGN but not in the ER.
Interestingly, we found that AP46 and AP40/42were differently affected by monensin,
NH4Cl, lactacystin, and tunicamycin. While these drugs displayed no or less inhibitory
effects on AP46 generation, they significantly blocked AP40/42generation, suggesting
that AP46 is likely generated at the earlier stage in the secretory pathway than AP40/42.

5.1 Introduction
Alzheimer's disease (AD) is a devastating neurodegenerative disease characterized by
extracellular deposition of amyloid plaques and intracellular formation of neurofibrillary
tangles. Overwhelming evidence supports the hypothesis that accumulation of AP, the
predominant component of amyloid plaques, plays a crucial role in the pathogenesis of
AD[ l , 1 8]. AP is derived from its precursor protein, a type I transmembrane(TM) protein
called P-amyloid precursor protein (APP) through sequential cleavages by P- and y
secretases. P-secretase librates the large N-terminal ectodomain of APP, generating the
C-terminal fragment of APP composed of 99 residues (CTFP or C99). CTFP is further
cleaved by y-secretase to generate AP40/42. Alternatively, APP can be cleaved at the
middle of the AP sequence by a.-secretase, resulting in soluble APPa. and membrane
bound CTF a.. CTF a. is subsequently processed by y-secretase to release a small peptide
with 24-26 residues called P3 that is not thought to be amyloidogenic [1]. Recently, we
have identified a novel presenilin dependent cleavage site, the /;-site, within the TM
domain of APP, generating Ap46 [ 139].
The subcellular sites for the generation of AP have been the subject of intensive research.
y-secretase that catalyzes cleavages in APP TM domain and determines the C-terminal
heterogeneity of AP is known to consist of at least four proteins, presenilin (PS),
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nicastrin, Aphl and Pen2. Presenilins (PSs) are believed to constitute the catalytic
subunit of y-secretase([89, 94, 95, 97, 98] ). Althouth PS 1 is predominantly located in the
endoplasmic reticulum (ER), the intermediate compartments, and the cis-Golgi
compartment [172-1 75], the major y-secretase activity has been shown to be in the late
compartments of the secretory pathway, at the cell surface, and in endosomes[l 76-1 79] .
After being synthesized in the endoplasmic reticulum (ER), APP matures and is
processed through the secretory pathway to the cell surface, where a portion of APP has
been shown to be reintemalized into endosomes/lysosomes through the endocytic
pathway. The early subcellular site for generating A� has been reported, in particularly in
neuronal cells, to be the ER and intermediate compartment(IC), where intracellular A�42
was generated [ 1 67, 1 80, 1 8 1]. Whereas overwhelming evidence has shown that the
major sites for generation of secreted A�40 and A�42 are in the Golgi/TGN and secretory
vesicles[1 67, 1 76, 1 82, 1 83].

A portion of A� has also been demonstrated to be

generated on the cell surface [1 84], and in endosomes/lysosomes through
reintemalization from the cell surface [1 77, 1 85]
Since the intracellular and secreted A� are known to be generated at distinct subcellular
sites [1 86, 1 87], little is known regarding the precise intracellular site in which A�46 is
generated. To better understand . the role of �-cleavage and the relationship between �
and y-site cleavages, it is necessary to determine the A�46 generation subcellular site.
Here we have examined the subcellular locations of A�46 generation using different
approaches. We found that A�46 was presented in 20k xg crude membrane pellet but not
in 20k xg supernatant, and the majority of A�46 was resistant to cell surface
trypsinization. Treatment with BFA abolished the production of A�46, whereas monensin
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treatment slightly affected AP46 level. Proteasomal inhibitor lactacystin, and
endosomal/lysosomol inhibitor NH4Cl did not block AP46 generation. Furthermore,
results from both transient transfection and stable clone showed that addition of an ER
sorting signal (KKQN) to the C-terminus of APPsw completely blocked AP46 generation
while addition of a TGN sorting signal sequence (SDYQRL) did not affect l;-cleavage.
Our data collectively suggest that AP46 is mainly generated in the Golgi/TGN
compartments in N2a cells.

5.2 Materials and Methods
5.2.1 Plasmid construction. cDNA fragments encoding organelle sorting signals either

KKQN( designated as APPsw-ER) or SDYQRL( designated as APPsw-TGN) C

terminally tagged APPsw695 were generated by

PCR based mutagenesis

usmg

APPswe695 cDNA as the tempelate. The cDNA fragments were ligated into Topo TA
cloning vector (lnvitrogen) and subcloned into Hindlll and Xbiol sites of pcDNA3.1
vector (invitrogen) to get APPsw-ER/pcDNA3. l and APPsw-TGN/pcDAN3.1 plasmids,
respectively. All cDNAs were verified by sequencing.
5.2.2 Cell lines. Mouse neuroblastoma cells lines stably expressing either human wild

type PS1 (N2aPS1wt) or both C-terminally myc tagged Swedish mutant APP and human
wild-type PS1 (N2a APPsw/PS1Wt) were established as described previously.
N2aAPPsw-ER/PS1wt and N2aAPP-TGN/PS1wt cell lines stably expressing human
wild-type pS1 plus Swedish mutant APP695 C-terminally tagged either with ER sorting
motif or with TGN sorting signal were established by transfection of N2aPS1wt cells
with either APPsw-ER/pcDNA3.1 or APPsw-TGN/pcDNA3.1 vectors and subsequent
selection of stable clones with G418 drug.
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5.2.3 Antibodies and chemicals.

Monoclonal antibodies 22C 1 1 and 6E 1 0 which

recognizes residues 66-8 1 of APP and residues 1 - 1 7 of the A� sequence were purchased
from Boehringer Mannheim and Senetek, respectively. Monoclonal antibodies anti-Bip
and anti-y-adaptin were from BD Transduction laboratories. Polyclonal antibody anti-Grp
was from Affinity Bioreagents. Polyclonal antibody C 15 against the last 1 5 residues of
APP was described previously[1 39]. Rhodamine Red-X-Conjugated anti-mouse antibody
and Alexa-Fluor 488 anti-rabbit antibody were from Jackson Immuno Research
Laboratories and Molecular Probes, respectively.
5.2.4 Preparation of crude membrane fraction. N2aAPPsw/PS 1 wt cells cultured in the

presence of 0.5 µM DAPT for 4 h were homogenized in homogenization buffer( 20mM
HEPES, pH7.4, 50mM KCl, 2mM EGTA, 1 0% glycerol with protease inhibitor cocktail)
[142] by passing through a 20 gauge needle 30 times. The homogenate was centrifuged
at 800 x g for 1 Omin to yield the 800 x g pellet (P800g) and supernatant (post nuclear
supernatant). The resulting supernatant was further centrifuged at 20k x g for 20min to
get the crude membrane fraction (P20kxg) and supernatant (S20kxg). Both P20kxg and
S20k xg fraction were dissolved in lysis buffer and equal amounts of protein . were
subjected to western blot.
5.2.5 Surface Trypsinization. N2aAPPsw/PS 1 wt cells grown in three 1 0-cm dishes at

,_,75% confluence were treated with 0.5µM DAPT for 4 h to accumulate A�46, followed
by washing with cold IX PBS twice. Cells were next incubated at 37 °C with 6mL 1 X
PBS (0.5µM DAPT), 3mL lX PBS plus 3mL0.25% trypsin-EDTA solution (Sigma), or
6mL 0.25% trypsin-EDTA solution (Sigma), respectively. Both IX PBS and 0.25%
trypsin-EDTA solution contained 0.5 µM DAPT to prevent accumulated A�46 and CTF�
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from turnover. After 30 min trypsinization, cells were collected in 20 mL fresh DMEM
medium containing 10% FBS, centrifuged to get cell pellet, and further washed with
20mL fresh medium twice before adding 0.5mL Lysis-buffer (50mM Tris-HCl, pH6.8,
2%SDS, 8M urea, 2mMEDTA, 2mM DTT, and protease inhibitor cocktail ). After brief
sonication, lysates were mixed with SDS-PAGE sample loading buffer and boiled at 100
°ಢC for 5.
5.2.6 Organelle toxin/inhibitor treatment.

N2aAPPsw695/PS 1wt cells that stably

express Swedish mutant APP695 and wild-type PS1 were grown in 10-cm dishes for 24 h
to reach semi-confluence in DMEM containing 10% FBS.

The media were then

replaced with fresh media containing either vehicle ( as a control) or one of the following
inhibitors: 10 µM brefeldin A (BFA,10 mM stock solution in DMSO, Sigma), 5 µM or
10 µM monensin (10 mM stock solution in ethanol , Sigma), 10 mM or 25 mM N"4Cl
(5M stock solution), 10 µM lactacystin (10 mM stock solution in DMSO, Calbiochem),
or 10 µg/ml tunicamycin ( 10 mg/ml stock solution in DMSO, INC Biomedicals) as
indicated in each figure. After culturing for 8 h, the conditioned media were collected,
and the cells were scraped in Lysis Buffer (50mM Tris-HCl, pH6.8, 2%SDS, 8M urea,
2mMEDTA, 2mM DTT, and protease inhibitor cocktail(Roche) ) containing 0.5 µM
DAPT (Calbiochem) , briefly sonicated, mixed with sample loading buffer, and boiled for
western blotting
5.2.7 Immunoprecipitation and western blotting. Western blotting was performed

essentially as described previously [139]. 7.5% SDS-PAGE was used for analysis of
soluble APP fragments or nicastrin; 8-18% gel was used to analyze C-terminal fragments
of APP or A� peptides; 10% Bicine/urea SDS-PAGE system was employed to separate
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A� species as described previously[l 39].
5.2.8 Immunofluorescence microscopy. N2aAPPsw/PS lwt cells grown on microscope

cover glasses (Fisher brand) in the presence or absence of 10 µM BFA or 5 µM monensin
for Sh, or the cells that stably express C-terminally tagged APPsw (APP-ER and APP
TGF) grown on microscope cover glasses, were fixed with 4% paraformaldehyde at room
temperature for 30 min, followed by washing with cold lX PBS three times. The fixed
cells were permeabilized with 0.3%Triton X 100 for 5 min , washed with cold PBS three
times, and blocked with blocking solution (5% lamb serum, 0. 1% Tween, l X PBS) at
room temperature for 45 min. The cells were next incubated with appropriate primary
antibodies (as indicated in each figure) in blocking solution at 4 °C overnight and washed
with lX PBS containing 0.075% tween-20 five times. Cells were then incubated with
either Rhodamine Red-X-Conjugated anti-mouse antibody (Jackson immuno Research
laboratories) or Alexa-Fluor 488 anti-rabbit antibody (molecular probe) for 1 h followed
by washing with lX PBS containing 0.075% tween -20. The cells were visualized under
Niko Eclipse E600 microscope and immunofluorescence images were captured using
Qcapture software.

5.3 Results
5.3.1 AP46 is present in the crude membrane fraction. Having shown that major A�46

is detected in total cell lysates but not in conditioned medium [139], prompted us to
determine the intracellular compartments of A�46 generation. We first performed a brief
centrifugation to separate cytosolic proteins from the large membrane. As shown in
FiglA, CTF� was detected in both supernatant and pellet, consistent with previous report
that ·�-secretase shows highest activity in various compartments including Golgi, TGN,
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and secretory vesicles[72]. In contrast, A�46 was only detected in P20k xg fraction,
suggesting that A�46 is predominantly located in large membrane compartments such as
the ER, the Golgi/TGN, or the plasma membrane. Similar results were reproduced from
compound E treated cells (data not shown), indicating that y-secretase inhibitors do not
alter the localization of A�46. Interestingly, both PS1 and Nicastrin were also mainly
detected in 20k xg pellet fraction (data not shown), indicating that A�46 may be co
localized with the y- secretase complex.
5.3.2 The majority of AP46 is resistant to surface trypsinization. We next determined

whether Af346 resides on the cell surface by employing cell surface trypsinization as
described by other investigators [184, 187]. Both A�46 and CTF� contain three putative
cleavage sites for trypsin (the region outside of the plasma membrane): 5Arg , 16Lys,
and 28 Lys of the A� sequence. Cleavage at 5Arg would result in a small A� or a CTF
fragment, whereas cleavages at 16Lys or 28Lys destroy the recoganization for 6E10. We
found that surface trypsinization dramatically decreased the CTF� level (Fig2, lanes2-3),
especially at high doses of trypsin (Fig2, lane 3). This suggests that CTF� accumulated
by treatment with DAPT is mainly localized on the cell surface, or it may be derived
from cell surface localized APP during the last 30 min before lysis. In contrast, the A�46
level was only slightly reduced by cell surface trypsinization, even at high dose of trypsin
(Fig2, lanes 2 and 3). This finding indicates that A�46 is mainly present in intracellular
compartments, and only a small portion of A�46 exists on the cell surface.
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5.3.3 Treatments with BFA and monensin block APP secretion in N2a cells, whereas
lactacystin, ammonium chloride, and tunicamycin do not inhibit APP secretion.
Although the brief centrifugation and surface trypsinizaiton gave us a clue of the
localization of A�46, the place in which A�46 exists may not truly reflect the subcellular
compartments in which the A�46 is generated, thus we employed protein trafficking
inhibitors to investigate the sites of A�46 generation. Both BFA and monensin have been
widely used to study protein trafficking pathway. The fungal metabolite BFA has been
shown to block anterograde transport and maturation of APP between the ER and the
Golgi[1 87- 1 89], causing the proximal Golgi to fuse with the ER, and the TGN to fuse
with endosomes. Ionophore monensin is known to block protein trafficking and
maturation within the GolgiffGN, and neutralizes some acidic intracellular compartments
such as the TGN, lysosomes, and certain endosomes[1 90, 1 9 1]. To investigate whether
these inhibitors cause retention of over-expressed Swedish mutant APP in certain
compartments in N2aAPPsw/PS 1 wt cells, we first cultured cells in the presence or
absence of these inhibitors for 5 h, followed by double immunofluorescence staining of
the cells with anti-APP antibody (6E 1 0 or C- 1 5) plus either anti-Grp/Bip antibody or
anti-y-adaptin antibody to examine the localization of APPsw protein in N2a cells.
Grp78/Bip (glucose-regulated protein 78 or immunoglobulin binding protein) is a well
characterized ER chaperone[1 92, 1 93], whereas y-adaptin is a TGN resident protein[ l 94] .
As shown in Fig3, over-expressed APPsw in untreated N2a cells did not co-localize with
Grp, but a portion of APPsw did co-localize with y-adaptin, which is in agreement with
previous reports showing that APP is concentrated in the Golgi complex [ 1 95] . As
expected, treatment with BFA led to co-localization of APPsw with Grp/Bip, whereas
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treatment with monensm resulted in the co-localization of APPsw with y-adaptin,
indicating that BFA and monensin treatments retain over-expressed APPsw
predominantly in the ER and TGN in N2a cells, respectively, which is consistent with
other's observations[l95].
We next examined the effects of BF A, monensin, lactacystin, ammonium chloride and
tunicamycin on APP secretion. N2aAPPsw/PS 1wt cells were treated with these inhibitors
at indicated concentrations for 8 h. Then both conditioned media and cell lysates were
analyzed by western blot. Consistent with previous reports[195], treatment with BFA led
to elevated levels of intracellular full-length APP (Fig3A. lane 2 in all three panels) and
completely abolished APP secretion (Fig4B, lane 2 in both panels), indicating that APP
processing occurs after it leaves the ER. Interestingly, two clear bands were observed
from monensin treated cell lysate when probed with 6E10 antibody (Fig4A top panel,
lanes 3-4), whereas only the top band was shown when probed either with C15 antibody
or with anti-myc antibody (Fig4A, medium and bottom panels, lanes 3-4). As myc is
tagged at the C-terminus of APPsw, and C15 antibody recognizes the C-terminal 15
residues of APP, the band that only can be detected by 6E10 (Fig4A, top panel, lanes3-4,
lower band), but not by C15 and anti-myc antibodies is most likely the N-terminus of
APP cleaved at the a-site (APPa), because �-secretase generated N-terminal fragment of
APP, APP�, can not be recognized by 6E10, whereas y-secretase mediated cleavages are
believed to occur after �- or a-cleaveges. Although the total secreted APP (detected with
22C11 antibody which recognizes residues 66-81 of APP) was reduced in the conditioned
media from monensin treated cells (Fig4B, compare lanes3-4 with lane 1), APPa
(detected with 6E10 which recognizes residues1-17 of A� sequence) secretion was
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slightly increased as compared with that from untreated cells (Fig4B, bottom panel,
compare lanes 3,4 with lane 1). The increase of secreted APPa may not be due to the
failure of monensin to block APP secretion, but because of the markedly elevated
intracellular level of APPa (Fig4A, top panel, lanes3, 4). Retention of APPsw within the
TGN by treatment with monensin elevated level of full-length APP, the substrate of a
secretase, as a result of the inhibition of APP nonspecific degradation (Fig4 A, lanes3,4
in all three panels), thus leading to increased level of a-secretase cleavage product, AP Pa.
This finding also confirms previous observations that the TGN is one of the major
subcellular compartments for a-secretase mediated APP processing [70, 196, 197].
Treatment with monensin slowed protein secretion but did not completely abolish protein
trafficking, which is consistent with previous observations[ 190, 191]. Inhibition of the
proteasome with lactacystin[ l 98] did not alter APP secretion (Fig4B, lane5 in both panel),
however, lactacystin slightly decreased full-length APP level (Fig4A, compare lane5 with
lane 1 in the medium and bottom panels). The reason why the inhibition of the
proteasomal degradation pathway affects exogenous APP expression is currently unclear.
However inhibition of the proteasomal degradation pathway may result in several effects
such as apoptosis, and differentiation of neuroblastoma cells[ 199].
Since the endosomal/lysosomal pathway has also been shown to be involved in APP
processing [ 185, 200], the effect of NH4Cl on APP secretion was also examined. As
shown in Fig4B (lanes 6, 7 in both panels), NH4Cl treatment did not block, but rather
slightly increase APP secretion. Interestingly, when we examined intracellular APP level
with 6E10 antibody, we found two bands from NH4Cl treated samples (Fig4A, top panel,
lanes 6,7). However the lower band was not recognized by C 15 or anti-myc antibodies,
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suggesting that it is most likely APPa (Fig4A, medium and bottom panels, lanes6,7). The
similar patterns obtained from monensin and NH4Cl treatments suggest that their effects
overlap to some extent. However, the lower band in Fig4A, top panel, lanes 6, 7 shows
lower mobility than the lower band in lanes3,4 of Fig4A, top panel, which possibly
results from different post-translational modifications of APPa. Monensin treatment
partially blocks APP post-translational modification of APP [191], thus leading to lower
molecular weight APPa, whereas NH4Cl treatment mainly affects endosomal/lysosomal
functions, and would be less likely to affect post-translational modification. This finding
also suggests that immature APP can be processed by a-secretase.
Since APP contains two potential N-glycosylation sites at Asn467 and Asn 496, we also
incubated cells with tunicamycin, which blocks cotranslational N-glycosylation within
the ER[201]. However, inhibition of APP secretion was only observed when detected
with 6E10(Fig4B,bottom panel, lane8), but not with 22C l l (Fig4B top panel, lane8),
suggesting that inhibition of N-glycosylation of APP only affects a-secretase mediated
processing but not �-site cleavage.
5.3.4 BFA treatment abolishes AP46 generation, monensin only slightly reduces
AP46 level, whereas ammonium chloride, lactacystin and tunicamycin do not affect
AP46 generation. To investigate the subcellular locations of A�46 generation, we treated
cells with the above described trafficking or organelle inhibitors in the presence or
absence of compound E, then analyzed their effects on A�46 generation. We employed
both regular 10/18% SOS-PAGE and 10% Bicine/urea SOS-PAGE systems to confirm
the identities of intracellular A�, and standard A�40/42markers were also included. As
expected, treatment with compound E led to intracellular accumulation of A�46 (Fig5A,
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lane 9 in both panels). Surprisingly, treatment with BFA completely abolished A�46
generation (Fig5A, lanel O in both panels). Although A�42 has been reported to be
generated in the ER in several cell lines[l 67, 180, 181], A�42 generated in the presence
of BFA was undetectable by directly loading lysate without immunoprecipitation (Fig5A,
top panel, lane10), demonstrating that both A�46 and A�42/40 are less likely generated
in the ER from full-length APP in N2a cells.
We next examined whether retention of APP at the Oolig/TON by monensin affects
A�46 production. As shown in Fig5A lanesl l and 12, in both panels, 5µM monensin
largely did not affect A�46 level, whereas 10µM monensin reduced A�46 produciton.
Since monensin is known to inhibit TON function [191], these findings suggest that
A�46 can be generated in Oolgi and TON subcellular sites. There are at least two
possibilities for the reduction of A�46 at high concentration of monensin: 1) A�46 is
predominantaly generated in the Oolgi and TON, but high concentration of monensin
affects the generation of A�46 in TON as a result of inhibition of TON function by
monensin; 2) a portion of A�46 may be generated downstream of the TON. It is noted
that the CTFP level was dramatically decreased in monensin treated cells, especially at
high concentration of monensin (Fig5A, lanes 11, 12 in both panels). Thus the reduction
of A�46 generation at high concentration of monensin is very likely due to the inhibition
of �-secretase mediated cleavage, rather than �-cleavage.
We also examined the effect of lactacystin on A�46 production, as shown in Fig5A
lane13 in both panels, although CTF� level was decreased, inhibition of the proteasome
with lactacystin did not reduce A�46 level, indicating that the proteasome is not involved
in generation of A�46. To examine whether endosomes/lysosomes are involved in A�46
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production, we also treated cells with both NH4Cl and compound E. As shown in Fig4A
lanes 14 and 1 5 in both panels, 25mM NH4Cl did not inhibit A�46 production, indicating
that endosomes/lysosomes are not involved in A�46 generation. Tunicamycin did not
affect A�46 level (Fig5A, lane 1 6 in both panels), suggesting that N-glycosylation of
APP is not required for generation of A�46.
The effects of these inhibitors on the level of AICD were also determined. No C-termini
of APP were observed in BFA treated cells even cultured in the presence of y- secretase
inhibitor compound E (Fig5B,both panels, lane 1 0), indicating the absence of any
secretase-mediated processing in the ER. In contrast to BFA, treatment with monensin
led to elevated level of both endogenous and exogenous AICD (Fig5B, lanes3,4,6 and 7),
demonstrating that e-cleavage of APP occurs before APP exits from the TGN. A
conceivable reason for the increase of AICD in monensin treated cells is that monensin
treatment prevents AICD from leaving the Golgi/TGN for downstream degradation, since
AICD is known for its very short half life.

As expected, inhibition of

endosome/lysosome function with NH4Cl dramatically enhanced accumulation of AICD,
confirming that AICD is unstable, and the major site for degradation of AICD is
endosomes/lysosomes. Consistent with previous finding, y-secretase inhibitor compound
E partially blocked e-cleavage, thus diminished AICD generation (Fig5B compare
lanesl 1 , 1 2,14, 1 5 with lanes3,4,6,7)
5.3.5 AP46 and Ap40/42are differentially affected by monensin, NH4Cl, lactacystin,
and tunicamycin. We then examined the effects of these inhibitors on A�40/42secretion.

Similarly to the effect of BFA on A�46, we did not find any A� species in the
conditioned medium (Fig5C, lane3) or the lysate (Fig5A, lane3 in both panels) from BFA
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treated cells. Although A�42 has been reported to be generated in the ER [167, 181, 202],
we and others did not confirm these findings[ l 72, 203-205]. Although we can not rule
out the possibility that a trace amount of A�42 may exist in the lysate of BFA treated
cells, as we directly loaded the lyaste without immunopreciation, the amount of
intracellular A�42 must be very low, since the endogenous level of A�46 was seen under
the same condition. Thus our result demonstrates that the ER is not a major site for
generation of A�40 or A�42 (Fig5A, lane1 in both panels). Interestingly, 5 µM monensin
which displayed almost no inhibitory effect on A�46 level (Fig5A, lane 11), clearly
reduced A�40/42production (Fig5C, lanes4 and 7), whereas 10 µM monensin almost
completely blocked both A�40 and A�42 secretion (Fig5C, lane4), indicating that the
subcellular site for generation of A�46 is different from that for A�40/42. In addition,
NH4Cl treatment, which exhibited no effect on A�46 production under the test condition,
led to a dose dependent inhibition of both A�42 and A�40 generation, further indicating
that the site for A�46 generation is at earlier stage in the secretory pathway than that of
A�40/42. Furthermore, inhibition of proteasomes with lactacystin, and inhibition of N
glycosylation with tunicamycin all blocked A�40/42generation (Fig5C, lanes 6 and 9),
while these drugs exhibited no effect on A�46 generation (Fig5A, lanes 13 and 16),
suggesting that A�46 and A�40/42are generated at distinct subcellular sites or by
different enzymes. The parallel inhibition of both A�40 and A�42 for all the tested
inhibitors suggests that A�40/42may be generated at the same compartments in this cell
line.
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5.3.6 Retention of APP in the ER by ER sorting motif diminishes both AP46 and
AP40/42generations, whereas addition of TGN sorting sequence to the C-terminus of
APP does not affect AP46 or Ap40/42generation. It is noted that trafficking inhibitors

BFA and monensin block all protein transport and maturation, and monensin treatment
leads to the inhibition of acidification of the TGN and lysosomes. To exclude the
possibility that the inhibition of A�46 generation by BFA is due to the blockage of the
maturation of other components that are required for A�46 generation, and under normal
conditions, these components can reenter the ER after maturation, we generated an
expression vector encoding Swedish mutant APPsw C-terminally tagged with ER
sorting signal KK.QN(designated as APPsw-ER), which has been known to effectively
retain protein in the ER[ 1 80, 204, 206, 207]. To confirm the major site for A�46
generation is the Golgi/fGN, we constructed an expression vector encoding Swedish
mutant APP C-terminally tagged with TGN sorting signal SDYQRL(designated as
APPsw-TGN), which is known for retention of protein in the TGN [208, 209]. N2aPSlwt
cells stably expressing human wild-type PS 1 were transiently transfected with either
APPsw-ER, APPsw-TGN, APPsw, or Lacz ( all in pcDNA3. 1 plasmids), respectively,
and cultured in the presence or absence of 3nM compoundE or O.SµM L685,458 for 12h,
followed by analysis of APP processing by western blotting.
We first examined the expression and secretion of APP in transiently transfected cells.
Consistent with the trafficking inhibition results and findings of other using the same ER
sorting signal[204], retention of APP within the ER diminished

APP secretion

(Fig6A,top panel, lanes 4-6), whereas retention of APP in TGN did not affect APP
secretion but rather slightly increased secretion as compared with APPsw vector( Fig6A,
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top panel, lanes7-12). When we determined the APP level in lysates, we found a
concomitant increase of full-length APP in APPsw-ER transfected cells (Fig6A bottom
panel lanes 4-6) and a concomitant decrease in APPsw-TGN transfected cells (Fig6A,
bottom panel, lanes7-9). Due to the less homology between mouse APP and human APP
within the 1-1 7 residues of the A� sequence, we did not detected the mouse endogenous
APP in Lacz transfected cells (Fig6A, lanesl-3 in both panels) when probed with 6E10.
We next determined the effect of ER or TGN sorting signals on A�46 generation. No
CTF-� or A�46 band was detected in lacZ transfected cells when probed with 6E10
(Fig6B, lanesl-3). Although a small portion of CTF�-ER was seen (Fig6B lanes4-6),
only a very faint A�46 band was observed in APPsw-ER transfected and compound E
treated cells (Fig6B lanes4-6), indicating that A�46 is not generated in the ER. Consistent
with the result of monensin treatment, addition of TGN signal did not affect A�46 level
(Fig6B, compare lane8 with lane 10), confirming that the major location of A�46
generation is within or upstream of the TGN.
We also examined the secreted A� level in these different vector transfected cells. We
found that addition of TGN sorting signal did not affect total A� production (FigSC,
compare lane7 with lane l 1) or A�42 level (Fig6D, compare lane 3 with lane4), while
retention of APP in the ER significantly diminished the generation of both total
A�( Fig6C, lane4) and A�42(Fig6D, lane2), which is also consistent with previous report
[204], indicating that both A�40 and A�42 are generated downstream of the ER, but
upstream of or within the TGN.
To confirm the transient transfection results, stable clones expressing either APPsw-ER
or APPsw-TGN proteins were established by transfection of N2aPS1wt cells either with
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APPsw-ER or with APPsw-TGN plasmids, using G4 18 to select stable clones. Although
the amount of full-length APP in APPsw-ER clones was higher than that in APPsw-TGN
clones (Fig6E, top panel, compare lanesl -6 with lanes 7-1 2), neither AP46(Fig6E, lanes2
and 5, treated with compound E) nor AP40/42( Fig6F, lanes l and 2) was observed in
APPsw-ER clones, further confirming previous findings that retention of APP in the ER
diminishes AP generation and APP secretion[204, 210]. Both AP46 (Fig6E, lanes 8 and
1 1 , with compound E) and AP40/42 were clearly seen in the samples from APPsw-TGN
clones. This finding further confirms that retention of APP with an ER sorting signal
abolishes both AP46 and AP40/42generation, whereas addition of a TGN sorting signal
does not affect either AP46 or AP40/42production.
5.3.7 APPsw-ER and APPsw-TGN reside in the ER and the TGN in N2a cells,
respectively. To ascertain the localizations of APPsw-ER and APPsw-TGN proteins, we

performed double immunofluorescence microscopy using stable clones of APPsw-ER
and APPsw-TGN. As expected, APPsw-ER was co-localized with Grp78 protein, an ER
resident protein (Fig7), whereas APPsw-TGN was co-localized with y-adaptin (Fig7), a
TGN marker. These results confirm that APPsw-ER and APPsw-TGN locate in the ER
and the TGN in N2a cells, respectively.

5.4 Discussion
Although various subcellular compartments including the ER, the IC, the Golgi/TGN,
endosomes/lysosomes, and the cell surface have been demonstrated to be sites for AP
generation [167, 1 76, 1 77, 1 80, 1 82-1 85], it has been known that different AP species are
generated in distinct subcellular compartments,

and the sites for generation of

intracellular cellular and secreted AP are also different [ 1 67, 180, 1 8 1 , 1 82]. Previously
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we found a new A� species, sA� or A�46, which predominately exists in cell lysate but
not in conditioned medium. To better understand the mechanism of y-secretase mediated
cleavages, we have determined that Golgi/TGN is the major site for A�46 generation.
We first determined whether A�46 resides in large membranes, vesicles, microsomes, or
cytosol by centrifugation of post nuclear supernatant at 20k xg. Although CTF� was
found in both supernatant and pellet, A�46 was only seen in 20k xg pellet, indicating that
A�46 mainly exists in large membranes such as the ER/IC, the Golgi/TGN, or the cell
surface, but less likely in cytosol or microsomes. To examine whether A�46 resides on
the plasma membrane, we performed surface trypsinizaiton. Unlike CTF�, which was
sensitive to surface trypsinization, the majority of A�46 was resistant to surface
trypsinizaiton, indicating only a small amount of A�46 is located on the cell surface.
Since the localization of A�46 may not truly reflect the place where it is generated, we
employed BF A and monensin, two known protein trafficking inhibitors, to examine the
subcellular compartment for A�46 generation. Using double immunofluorescence
staining, we confirm that APP was co-localized with Bip or y-adaptin, after treatment
with BFA or monensin, respectively. Consistent with previous observations[l 95],
treatment with BFA diminished the APP secretion, and elevated the level of full-length
APP. In contrast, treatment with monensin reduced total soluble APP (sAPP� and sAPPa.)
level, but led to slightly elevated level of soluble APPa and accumulation of large
amounts of intracellular APPa fragment. Treatment with NH4Cl increased APP secretion
and intracellular accumulation of APPa, suggesting that NH4Cl inhibits the degradation
of APP in endosomes/lysosomes. We next examined A�46 level in various inhibitor
treated cells. Surprisingly, we found treatment with BFA completely abrogated A�46
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generation even in the presence of compoundE, indicating that A�46 can not be produced
in the ER. Monensin only exhibited inhibitory effect on A�46 generation at high
concentrations, suggesting that the site for Abta46 generation is in the Golgi and the TGN.
The partial reduction of A�46 generation at high dose of monensin was likely caused by
the blockage of A�46 generation in the TGN as a result of the inhibhition of TGN
function by monensin. The finding that the CTF� level from the cells treated with a high
dose of monensin was dramatically reduced (Fig5, lane 12 in panels A and B) favors this
suggestion.

Moreover, the fact that neither inhibition of endosomes/lysosomes with

NH4Cl nor inhibition of proteasome with lactacystin affected A�46 level, demonstrates
that A�46 is not generated in these organelles. Inhibition of N-glycosylation of APP by
tunicamycin did not reduce A�46 level, indicating that N-glycosylation is not required for
A�46 generation.
To further confirm that A�46 is generated mainly in the Golgi/TGN but not in the ER, we
added ER or TGN sorting motif to the C-terminus of Swedish mutant APP. Transient
transfection results show that addition of ER sorting motif diminished both APP secretion
and A�46 generation, whereas addition of TGN sorting signal did not affect A�46 level,
nor APP secretion, as compared with APPsw. APPsw-ER and APPsw-TGN stable clone
results also show that A�46 was only seen in APPsw-TGN cells but not in APPsw-ER
cells. Furthermore, co-localization of APPsw-ER with Bip/Grp and co-localization of
APPsw-TGN with y-adaptin were also observed by double immunofluoresence staining.
These findings demonstrate that retention of APP in the ER abolished A�46 generation
whereas retention of APP in the TGN did not affect A�46 level. Thus A�46 is
predominantly generated in the Golgi/TGN in this cell line.
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The finding that A�46 is generated in the Golgi/TGN is consistent with the previous
observations showing that �-secretase activity has been localized in the Golgi/TGN[72],
whereas assembled y-secretase complex has been reported to localize predominantly in
the Golgi and to a lesser extent, at the cell surface and in endocytic compartments [175,
210-212]
Another interesting finding of the present study is that s-cleavage and y-cleavage are
differentially affected by these inhibitors. As shown in Fig5, monenisn treatment at 5µm
did not affect A�46 level but clearly reduced A�40/42level, indicating that A�46 may be
generated at the earlier stage in the secretory pathway than A�40/42. The e-cleavage
product AICD was still seen when cells were treated with 10µM monensin, whereas
A�40/42level was almost completely blocked, suggesting e-cleavage of APP also likely
occurs at the earlier stage than y-secretase cleavage of APP. NH4Cl treatment results
further support the above suggestion, since 25mM NH 4Cl did not exhibited any
inhibitory effect on A�46 and AICD generation, while both A�40 and A�42 levels were
dramatically diminished by NH4Cl. These observations indicate that both

E-

and s

cleavages of APP occur at earlier stage of the secretory pathway than that of y-cleavage
of APP. Lactacystin and tunicamycin treatments exhibited similar results on
A�40/42level but did not affect A�46 generation, indicating that A�46 and A�40/42are
generated at distinct subcellular sites or generated by similar but different enzymes.
Taken together, our data indicate that A�46 is generated at the Golgi and TGN
compartments, whereas A�40 and A�42 are likely generated at the TGN and downstream
compartments. This finding may provide insight for explaining the discrepancy between
the localization of PSs and the A� generation sites.
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Name
y40-I
y40-II
y-lV
y-V

y-VI

y-IX

Synonyms
-3,5-DMC-IL-CHO
N-ter-Butyloxycarbonyl-Gly-ValValinal
2-Naphthoyl-VF-CHO
Z-LF-CHO
1-(S}-endo-N-(1,3,3)Trimethylbiocyclo[2.2.1]
hept-2-yl}-4-fluorophenyl
Sulfonamide

Structure or sequence
trans-3,5-DMC-Ile-Leu-CHO
BOC-Gly-Val-Val-CHO

Fianl concentration
20 µM
lO0 µM

2-Naphthoyl-Val-Phe-CHO
Z-Leu-Phe-CHO

25 µM
25 uM
20 µM

DAPT
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y-XII
y-XIII
y-XIV
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Z-YIL-CHO
Z-C(t-Bu}-IL-CHO

y-XVI

DAPM

�

8--QF

0

F

y-X

-�

�

,i:;2-.

0.5 µM

0.5 µM

0

N

100 µM

O

� CH3
O
Cl

Z-Ile-Leu-CHO
Z-YIL-CHO
Z-Cys(t-Bu}-Ile-Leu-CHO

'

40 uM
50 µM
1 .0 µM

� 0 :<o,cH,

0. 1 µM

y1!

y-XVII

3 1 C, WPE-III-3 1C

y-XVIII

Compound E

y-XIX

(2S,3R}-3-(3,4-Difluorophenyl)2-(4-fluorophenyl}-4-hydroxyl-N((3S)-2-oxo-5-phenyl-2,3dihydro-l H-benzo[e][l ,4]
diazepin-3-yl)-butyramide

Ibuprofen

2-(4-Isobutylphenyl)-propionic
Acid

Sulind
sulfide

Z-5-Fluoro-2-methyl1-[p-(methylthio)
benzylidene]
indene-3-acetic acid
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Chapter 1 Fig.1. Some known mutations in APP [1 ].
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Chapter 2 Fig.1. Detection of a new intracellular AfJ species. APP derivatives in

lysates or media of cells treated with (lanes 2 to 5) or without (lane 1 ) various inhibitors
(500 nM DAPT, 1 00 nM DAPM, 3 nM compound E (CPDE), and 5 nM XIX,
respectively) for 8 hrs were analyzed by 1 0- 1 8% Glycineffris-SDS-PAGE (top panels in
both Fig I A and B) or by Bicine/urea SDS-PAGE (bottom panels in both Fig 1 A and B).
Lane 6 is the mix of synthetic A�40 and A�42. Lane 7 is the synthetic A�43 . The top
panel in Figl A is the blot probed with APP C-terminal specific antibody C l 5, the other
three panels were probed with 6E l 0. Since the CTF� and CTFa derived from
recombinant APPsw are tagged with a myc epitope, they were detected as bands with
slower migration rates than the endogenous CTFa (CTFa(end))(top pane). The bottom
panel in Fig 1 A is the secreted A� immunoprecipitated from CM.

1 10

HEK293 HS683 Mt 7 N2aAPPmyc
CPDE
+
+ - + - +
--fAPP

�CTEB_-', myc
---CTFJ3
--A 4 0
--A;, 42

�A 46_
l

2

3

4

S

6

7

8

9

Chapter 2 Fig.2. Detection of the novel AfJ species from several cell lines. Cell lysates

of HEK293 (lanesl ,2), human glioma HS683 (lanes 3 and 4), and human neuroblastoma
Ml 7 (lanes 5 and 6) cells treated with (3 nM) or without (-) compound E (CPDE) as
indicated for 8 hrs were analyzed for the presence of the new A� species. As controls,
cell lysates of N2a cells stably expressing APPsw and PS 1 wt treated with (lane 8) or
without (lane 7) compound E were included. Lane 9 is the mix of synthetic A�40 and
A�42.
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Chapter 2 Fig.3. MALDI-MS spectrum for the novel AP species. Mass spectrometric

analysis was performed as described previously[133] except that after applying the
sample matrix solution to the sample plate, formic acid and isopropanol were added to a
final concentration of 30% each.
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fPS 1

fAPP-

AJ346sAP P-

Af3Chapter 2 Fig. 4. Dominant negative form of PSI diminishes Ap46 generation. Cell

lines are labeled at the top. Lysates of cells cultured in the presence (+) or absence (-) of
0.5 µM DAPT were analyzed by Western blot for the expression of PS l (top panel) using
anti-PS lN, which is specific for the N-terminal domain of PS l and was raised against a
peptide of 24 amino acids corresponding to residues 27-50 of human PS l . Full-length
APP, CTF�, and A�46 in the cell lysate were detected by 6E 1 0 (middle panel). Secreted
A� and soluble APP (sAPP) immunoprecipitated from CM were also detected by 6E1 0
(bottom panel). The two bands between sAPP and A� are the heavy chain and light chain
of IgG (bottom panel).
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Chapter 2 Fig.5. Double knockout of PS1/PS2 abolishes AfJ46 generation. PS 1 /PS2

wild-type or double knockout cells were transiently transfected with either Lacz or
APPsw vectors and cultured in the presence or absence of compound E for 1 2 h. The
lysates were separated either on 1 0/1 8% SDS-PAGE (top panel) or on 1 0%Bicine/urea
SDS-PAGE and probed with 6E 1 0 antibody. Note that A�46 was only seen in wild-type
(lane8) but not PS double knockout cells (lane4).
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Chapter 2 Fig.6.

Deferential inhibitions of AP46 formation by transition state

analogs and nontransition state inhibitors. Accumulation of CTF� and the new

intracellular A�46 (upper panel) and the secreted A�40 and A�42 immunoprecipitated
from CM with 6E 1 0 (lower panel) were analyzed by 1 0% Bicine/urea PAGE followed by
Western blotting using 6E 1 0. Inhibitors and concentrations used are indicated on the top
of the gels. Lanes 1 , 9, and 1 9 are controls of samples from untreated cells. Lanes 1 8 and
28 are the mix of synthetic A�0 and A�42 used as standards.
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Chapter 2 Fig.7. The Indiana mutation of APP enhances AIJ46 generation. N2a cells

were transiently transfected either with APPsw695 or with APPswN717F vectors and
cultured in the presence or absence of 3 nM compound E. Lysates (top panel) and
immunoprecipitated secreted A� species from CM (bottom panel) were separated on 10%
Bicine/urea SDS-PAGE and probed with 6E10. Lane 5 is the mixture of synthetic
A�40/42.
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Chapter 3 Fig.1. The absence of AP46 in cells treated with L- 685,458 is due to its
inhibition of the formation of AJ346. Both cell lysates (top panels) and the secreted
A�40/42immunoprecipitated from conditioned medium (CM) (bottom panels) were
analyzed by 1 0% Bicine/urea-SDS-PAGE. Lane 1 is the control (Ctr) of cells cultured in
absence of any inhibitors. Lane 1 5 is the mix of synthetic A�O and A�42.
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Chapter 3 Fig.2. AP46 turnover in a cell-free system. Membranes were prepared as
described in the "Experimental Procedures". Membranes were incubated at 3 7 °C or 0°C
for 1 hr. Samples were analyzed by 1 0-1 8% regular SOS-PAGE followed by Western
blotting using 6E 1 0. Lanes 1 -4 were one batch and lanes 5-1 1 were another batch.
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Chapter 3 Fig.3. Generation of secreted AfU0/42 from Ap46. L, L-685,458; DM,

DAPM; upper panel, cell lysates; bottom panel, A� immunoprecipitated from CM; lane
1 1 , the mix of synthetic A�40 and A�42.
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Chapter 3 Fig. 4. Schematic diagram of the procedure of crude membrane
preparation and solubilization
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Chapter 3 Fig.S. AP46 is associated with PSl. Cell lysate fractionation and co
immunoprecipitation were performed as illustrated in Fig.4 and described in "Materials
and methods". The resulting fractions and immunoprecipitates were analyzed by 1 0- 1 8%
SDS-PAGE for A�46 (Fig. 5A and. 5C) and for the C-terminal fragment of PS l (PS l L)
(Fig. 5D) or 1 0% SDS-PAGE for PS lN (Fig. 5B) followed by western blotting. A�46
and CTF� were detected with 6E l 0. In Fig. 5B, PS l was detected with anti-PS lN, which
recognizes the N-terminus of PS l [ 1 39]. Lane 1 in Fig. 5C is the synthetic A�46. In Fig.
5D, PS l in the immunoprecipitates was detected with anti-PS l L, which recognizes the C
terminus of PS l [ 1 44] . Since both anti-PS lN and anti-PS l L are rabbit polyclonal
antibodies, the rabbit IgG was detected as heavy dark bands above the PS 1 L band in
lanes 2 and 3 of Fig. 5D.
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Chapter 3 Fig. 6. Detection of AP49 in intact cells and the production of secreted
AP40/42from AP49. A. Detection of A�49 in intact cells. N2a cells, which stably

express PS1wt, were transiently transfected with Lacz (lanes 1 to 3) or with APPsw645
(lanes 4 to 6), and the formation and turnover of A�49 and A�46 in the absence of
inhibitors (Ctr) or in the presence of compound E (E) or L-685,458 (L) were analyzed by
10-18% regular SDS-PAGE followed by Western blotting using 6E10. Lanes 7 and 8 are
Immunoprecipitates (IP) from lysates of N2a cells stably expressing APPsw and PS1wt.
Note, IP* indicates that immunoprecipitation was carried out in the presence of DAPT.
Lane 9 is the synthetic A�46. Lane 10 is the synthetic A�49. The synthetic A�49 was
used as a crude product because the purification was not successful, maybe due to its high
hydrophobicity. Fig.6B. Production of secreted A�40/42from A�49. N2a cells stably
expressing PS1wt were further transfected with APPsw645. Stable clones were selected
with both 0418 (for APPsw) and Hygromycin (for presenilin). Secreted A�40/42in CM
of both transiently transfected (lanes 2) and stably transfected cells (lane 5 and 6) was
analyzed by 10% Bicine/urea SDS-PAGE. Lane 1 and lanes 7 are the synthetic A�40/42.
Since 6E10 was used for both immunoprecipitation and Western blotting, the dark bands
in Fig. 6A (lanes 7and 8, between CTF� and fAPP bands) and in Fig. 6B (lane 2 to 6,
between A�40/42and sAPP bands) are the heavy chain and light chain of mouse IgG.
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Chapter 3 Fig.7. Schematic illustration of APP processing. L-685,458 specifically
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Chapter 4 Fig.I. Effects of DAPT, compound E, ibuprofen, and sulindac sulfide on
AP46 and CTFP accumulation. N2aAPPsw/PS 1 wt cells were cultured in the presence
or absence of y-secretase inhibitors as indicated for 1 0 h. Lysates were separated on
1 O/l 8%SDS-PAGE system. Panel A, top panel was immunoblotted with 6E 1 O; bottom
panel was the longer exposure of top panel. Panel B. immuno-blotted with C 1 5 . Ctrs
represents control; CpdE, lbu, SSide stand for Conpound E, Ibuprofen, and Sulindac
sulfide, represpectively.
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Chapter 4 Fig.2. Inhibition profiles of various y-secretase inhibitors on APP
processing. N2aAPPsw/PS1wt cells were cultured in the presence various inhibitors as

indicated in the figure for 10 h at concentration listed in Tabl except for 31C. A. Effects
of various y-secretase inhibitors on intracellular accumulation of A�46 and CTF� .
Lysates were analyzed by 10/18% SDS-PAGE and immunoblotted with 6E10( top panel),
and C-l 5(bottom panel), respectively. B. Effects of various y-secretase inhibitors on
soluble APP production. Conditioned media were separated on 8% SDS-PAGE, and
blotted with 22C l l (top panel), and 6E10 (bottom panel), respectively. C. Effects of
various y-secretase inhibitors on A� release. Immunoprecipitated A� species were
separated on 10% Bicine/urea SDS-PAGE and blotted with 6E10. Ctr stands for control
which was treated with DMSO without any y secretase inhibitors. Inhibitors full names
were listed in Tab1.
125

�

XVI

i i �

It)

XVII

xvm

XIX .

� i � i � i

It)

,10¥;'+ ...... At340

---A.1342

Chapter

4 Fig.3. Effects of inhibitor

concentration on AP42/40 ratio.

N2aAPPsw/PS 1 wt cells were cultured in the presence of various inhibitors at two doses
as indicated in the figure for 1 Oh. The secreted A� spaces were immunoprecipicated from
conditioned media and analyzed by 1 0% Bicine/urea SDS-PAGE system, immunoblotted
with 6E 1 0. The bottom panel is the longer exposure of top panel.
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Chapter 4 Fig.4. The profile of AP46 and CTFP after removal of y-secretase
inhibitors. N2aAPPsw/PS 1 wt cells were cultured in the presence of inhibitors as labeled
in the figure for 1 2 h to pre-accumulated A�46 and CTF�. Conditioned media were
removed and cells were washed with cold medium for two times. Fresh media with
appropriated y-secretase inhibitors (as labeled in figure, e g. "IV-IV") or without inhibitor
(labeled "-" in the figure, eg "IV- ") were added and incubated for 2h before harvesting.
Top panel: immunoprecipitated A� species from conditioned media were analyzed by
1 O¾Bicine/urea SOS-PAGE system and blotted with 6E 1 O.Bottom panel: The
corresponding lysates were analyzed by the same system as top panel. Note that pre
accumulated A�46 did not turnover after removal of compound E (Lane l 8, XVIII-) and
inhibitor XIX (Lane20)
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Fig.5. L685,458 and 31C differentially affected Ap46 turnover.

N2aAPPsw/PS l wt cells were grown in the absence (lanes l -3) or presence of either
DAPM (lanes4-6, 8, and 9) or L685,458(1ane 7) for 1 2h followed by adding either
L685,458(Lanes2,6,9) or 3 1 C( lanes 3 and 8) for 3 5min pretreatment. Conditioned media
were removed and washed with cold fresh media with (Lanes2,6, 7 ,9 with L685,456;
lanes 3,8 with 3 1 C; lane 4 with DAPM) or without(lanes l and 5) appropriate inhibitors
for two times (in about 20min). Then fresh media with or without inhibitors as labeled in
each lane were incubated with cells at 3 7 °C for 2h before harvesting conditioned media
and cells. Lanel O was treated with both L685,458 and Z-V AD from pre-treatment step.
Top panel: Lysates were analyzed by 1 0%Bicine/urea SOS-PAGE system and probed
with 6E1 0. Bottom panel: Immunoprecipicated A� species from each corresponding
medium were analyzed by the same system as top panel( DM and L represent DAPM
and L685,458, respectively). Note that reduction of A�46 in Lanes 6,8,9 correlates well
with increase on secreted A�.
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Chapter 5 Fig.1. AfJ46 is present in 20kxg membrane fraction. DAPT treatment and

detailed separation precudures were described in the method section. Equal amounts of
protein were separated on 10/18% SDS-PAGE, and probed with 6E10 antibody. The
lower

panel

is

a

part

of

the

longer
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Chapter 5 Fig.2. The majority of AP46 is resistent to surface trypsinization.Cells

surface trypsinized samples were separated on 1 0/18% SDS-PAGE and probed with
6E1 0 antibody. "Ctr" and "Tryp" denotes control (without trypsination) and cell surface
trypsinized samples, respectively.
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Chapter 5 Fig.3. Treatments of BFA and monensin lead to distribution of APPswe
into the ER and TGN in N2a cells, respectively. N2aAPPsw/PS 1 wt cells were grown

on microscope cover glasses in the presence of absence of 1 0 µM BFA or 5 µM monensin
for 5 h. Then the cells were co-immunostained with appropriate antibodies as described
in material and method section. ("Ctr" represents without trafficking inhibitor treatment)
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Fig 1 . effect of or�elle toxins on solubilable APP secretation

Chapter 5 Fig.4. The effects of BFA, monensin, lactasystin, NH 4CI, and tunicamycin
on soluble APP secretion. "Ctr", "BFA", "Mon", "Lact", and "Tuni" represent control,

brefeldin A, mo�sin, lactacystin, and tunicamycin, rep!esentively. N2aAPPsw/PS I wt
cells were cultured in the absence (control) or presence of inhibitors as indicated for 8h.
A: Lysates were separated on 8/1 8% two-step SDS-PAGE and probed with 6E l 0 (top
panel), C- 1 S(medium panel), and myc (bottom panel) antibodies. B: Conditioned media
were separated on 8% SDS-PAGE and probed with either 22C l I (top panel) or 6E l 0
(bottom panel)
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Chapter 5 Fig.5. The effects of BFA, monensin, Iactacystin, NH4Cl, and tunicamycin
on y-secretase mediated APP cleavages. N2aAPPsw/PS 1 wt cells were in the presence

of inhibitors as indicated for 8 h (lanes9- 1 6 in all with 3nM compound E). A: Lysates
were separated either on 1 0% Bicine/Urea SDS-PAGE (top panel) or on 1 0/1 8%SDS
PAGE (bottom panel) and probed with 6E 1 0. B: Lysates were separated on 1 0/1 8 SDS
PAGE and probed with C 1 5 antibody. The bottom panel is the longer exposure. C: A�
species were immunoprecipicated with 6E l 0, separated on 1 0% Bicine/urea SDS-PAGE,
and probed with 6E 1 0.Lane is synthetic A�40/42peptides
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Chapter 5 Fig. 6. Addition of the ER sorting signal to APP abolishes both AP40/42
and AfJ46 production whereas addition of the TGN sorting signal did not affect
AfJ40/42 and AfJ46 generation. N2aPSl wt cells were transfected with lacZ, APPsw-ER,

APPsw-TGN, or APPsw vectors ( all in pcDNA3. l ), respectively and cutltred in the
presence or absence of compound E or L685,456 as indicated for 12h. A: conditioned
media (top panel) or lysates (bottom panel) from transiently transfected cells were
separated on 8%SDS-PAGE, and probed with 6E10. B: Lysates were separated on 10%
Bicine/urea SDS-PAGE and probed with 6El O.C: A� species immunopreciated from the
conditioned media of transiently transfected cells were separated on 10/18%SDS-PAGE
and probed with 6E10. D: Secreted A� species immunopreciated from the conditioned
media of transiently transfected cells were separated on 10% Blcine/urea SDS-PAGE and
probed with 6El 0. E: Lysates (top panel) or secreted A� from stable clones as indicated
were separated on 10/18% SDS-PAGE and probed with 6E10. F: Secreted A� were
separated on 10%Bicine/urea SDS-PAGE and probed with 6E10
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APPsw-TGN C 1 5

APPsw-TGN y-adaptin

Overlap

Chapter 5 Fig.7. Co-localization of APPsw-ER with Grp78 and APPsw-TGN with y
adaptin. N2aAPPsw-ER or N2aAPPsw-TGN Stable cells were cultured on microscope

cover glasses and Co-immunuostained with appropriate antibodies as indicated.
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